Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats by John Ward (1258341) et al.
Mathematical Medicine and Biology Page 1 of 55
doi:10.1093/imammb/dqnxxx
Predicting tyrosinaemia: a mathematical model of
4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats
JOHN P. WARD∗
Department of Mathematical Sciences, Loughborough University, LE11 3TU, United
Kingdom
∗Corresponding author: john.ward@lboro.ac.uk
JOANNE L. DUNSTER
Department of Mathematics & Statistics, University of Reading, PO Box 220, Reading, RG6
6AX, United Kingdom
GIANNE DERKS
Department of Mathematics, University of Surrey, Guildford, GU2 7XH, United Kingdom
PRATIBHA MISTRY AND JOSE´ D. SALAZAR
Product Safety, Syngenta, Jealott’s Hill International Research Centre, Bracknell, RG42 6EY,
United Kingdom.
Nitisinone or 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione, is a reversible inhibitor of 4-
hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme important in tyrosine catabolism. Today, nitisi-
none is successfully used to treat Hereditary Tyrosinaemia type 1, although its original expected role was
as a herbicide. In laboratory animals, treatment with nitisinone leads to the elevation of plasma tyrosine
(tyrosinaemia). In rats and Beagle dogs, repeat low-dose exposure to nitisinone leads to corneal opacities
whilst similar studies in the mouse and Rhesus monkey showed no comparable toxicities or other treat-
ment related findings. The differences in toxicological sensitivities have been related to the upper limit
of the concentration of tyrosine that accumulates in plasma, which is driven by the amount/activity of
tyrosine aminotransferase.
A physiologically based, pharmacodynamics ordinary differential equation model of HPPD inhibition to
bolus exposure of nitisinone in vivo is presented. Going beyond traditional approaches, asymptotic anal-
ysis is used to separate the different timescales of events involved in HPPD inhibition and tyrosinaemia.
This analysis elucidates, in terms of the model parameters, a critical inhibitor concentration (at which
tyrosine concentration starts to rise) and highlights the contribution of in vitro measured parameters to
events in an in vivo system. Furthermore, using parameter-fitting methods, a systematically derived re-
duced model is shown to fit well to rat data, making explicit how the parameters are informed by such
data. This model in combination with in vitro descriptors has potential as a surrogate for animal exper-
imentation to predict tyrosinaemia, and further development can extend its application to other related
medical scenarios.
Keywords: nitisinone, 4-hydroxyphenylpyruvate dioxygenase, tyrosinaemia, rat, mathematical model,
PBPK/PD, asymptotic analysis.
1. Introduction
Nitisinone or 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione was originally discovered as a
member of the triketone class of herbicides (Lock et al., 1998). These herbicides are potent inhibitors of
© The author 2008. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.
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FIG. 1. Tyrosine catabolism pathway indicating fumarylacetatoacetase activity (*), the enzyme deficient in type I tyrosinaemia
patients. The schematic also indicates the inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) by nitisinone, thus pre-
venting the generation of maleyacetoacetate and fumarylacetoacetate and their metabolites.
plant 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme important in the synthesis of plasto-
quinones and α-tocopherol (Prisbylla et al., 1993; Schulz et al., 1993; Ellis et al., 1995). In mammals,
HPPD is mainly present in the liver and is involved in the catabolism of tyrosine, an amino acid found in
proteins from the diet. Today, nitisinone is used in the clinic to treat a rare hereditary metabolic disorder
(Hereditary Tyrosinaemia type 1), where patients present with symptoms caused by a deficiency of the
enzyme fumarylacetoacetase, an enzyme in tyrosine catabolism (Figure 1) (Lock et al., 1992; Holme
& Lindstedt S., 1998). Such a deficiency leads to the accumulation of fumarylacetoacetate, maleyace-
toacetoacetate and their associated derivatives. These electrophilic metabolites contribute to progressive
liver and kidney dysfunction as well as porphyria in patients. Treatment of patients with nitisinone pre-
vents the formation of these harmful metabolites (such as succinylacetone) by blocking an earlier step
in the tyrosine catabolism pathway. This form of treatment coupled with a tyrosine and phenylalanine-
restricted diet provides a favourable outcome, particularly in patients when diagnosed early (McKier-
nan, 2006); liver failure is controlled in 90% of cases and other disease-related manifestations are well
managed. Overall, nitisinone is well-tolerated in patients and has changed the clinical management of
Heredatary Tyrosinaemia type I by dramatically reducing the need for liver transplantation.
In laboratory animals, treatment with HPPD inhibitors leads to the inhibition of tyrosine catabolism
and consequently the elevation plasma tyrosine (tyrosinaemia). In rats and Beagle dogs, the main toxi-
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cological endpoints observed following short-term repeat dose exposure with nitisinone include corneal
opacities at low doses. Similar studies in the mouse and Rhesus monkey showed no comparable toxici-
ties or other treatment related findings (Lock et al., 1998). Interestingly, the differences in toxicological
sensitivities between these species cannot be readily explained by molecular structural or sequence dif-
ferences in the HPPD enzyme as these features are highly conserved (Lock et al., 2006). However, the
upper limit of the concentration of tyrosine that accumulates in plasma does vary between mammalian
species, and studies have described these differences to be driven by the amount/activity of tyrosine
aminotransferase (TAT, see Figure 1), an enzyme important in the conversion of tyrosine to hydrox-
yphenyl pyruvic acid (HPPA) (Lock et al., 1996, 1998, 2000; Lewis R.W. & Botham J.W., 2013). Inter-
estingly, humans deficient in TAT, referred to as Richner-Hanhart syndrome, also present with corneal
opacities if dietary phenylalanine and tyrosine is not restricted (Goldsmith, 1983; Sammartino et al.,
1987). In the clinic, plasma tyrosine concentrations in patients with type I tyrosinaemia are maintained
at less than 500 mole/L (McKiernan, 2006; Mitchell et al., 2001). Since we are primarily interested
in understanding the intrinsic dynamics of the tyrosine catabolism pathway, we will assume that the
concentrations of the TAT enzyme will remain constant in the chosen animal system during HPPD inhi-
bition. However external influences on TAT (e.g., circadian rhythms, diet, etc.) can be readily included
and will be discussed in the last Section.
Animal studies are often used to understand the potency of new HPPD inhibitors via the extent of ex-
posure in circulating blood and the resulting tyrosinaemia. In addition, standard physiologically-based
pharmacokinetic-pharmacodynamic (PBPK-PD) approaches can offer information on the kinetics of the
inhibitor concentration and tyrosine dynamics across organs which are represented as compartments. In
this paper we extend the classical PBPK-PD approach by modelling the most relevant enzymatic reac-
tions in the liver in greater detail than is usually done (see Section 2) and utilizing asymptotic analysis
to determine the critical events that take place at each of the time scales of the full inhibition-recovery
process (see Section 3). This kind of analysis allows us to understand qualitatively the phenomena un-
der study without precise measurements on the parameter values. In Section 2, by making some generic
assumptions based on nitisinone experimental data, we are able to derive a number of interesting con-
sequences from the model. The asymptotic analysis carried out in Section 3 then provides key insights
such as a prediction of the critical inhibitor concentration at which tyrosine concentration starts to rise,
Equation (3.35), or a simple description of the inhibitor profile, Equation (4.1). Then in Section 4 we
fit the model to nitisinone experimental data, in order to estimate actual parameter values. The results
indicate that only certain parameter combinations are identifiable from the available experimental data.
Finally, in Section 5, we explain how to use our model as a virtual test bed for the development of new
HPPD inhibitors by utilizing information already available together with in vitro measurements. As
such, the key utility of this work is to serve as a surrogate for animal experimentation for new HPPD
inhibitors in early research, as well as a base model to adapt for repeat dose exposure scenarios and to
support human risk assessment activities.
2. Model Formulation
In this section we construct a kinetic model of the tyrosine degradation pathway and the effects of
a HPPD inhibitor. The model consists of a system of ordinary differential equations which describe
the changes in concentration of the various molecules involved in the reactions. A schematic of these
reactions is shown in Figure 2 and the variables and parameters are listed in Tables 1 and 2 respectively.
The appendix lists some parameter values from the literature.
The model is subdivided into three compartments representing blood (volume VB), tissue (volume
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Variable Description Unit
TB Tyrosine in blood M
TL Tyrosine in liver M
TT Tyrosine in tissue M
Hp Hydroxyphenyl pyruvic acid (HPPA) M
Ho 4-Hydroxyphenylpyruvate acid (HPPD) M
IB HPPD inhibitor in blood M
IL HPPD inhibitor in liver M
IT HPPD inhibitor in tissue M
A Tyrosine aminotransferase (TAT) M
R Homogentistic acid M
C Complex formed from Ho and Hp M
Table 1. Definitions and units of the variables. In the units column, M stands for molar (moles per liter.
VT ) and the liver (volume VL).
• Tyrosine, an amino acid that forms part of all proteins and is a precursor of neurotransmitters,
is produced by muscle tissue (rate T1) and obtained from diet (rate T0). It is present in blood
(concentration TB) and tissue (TT ), but mainly in the liver (TL) where it is broken down, (note that
this implies that the total measure of tyrosine in the blood is given by VBTB and similar measures
apply for tyrosine in the tissue and liver). We assume tyrosine decays in the tissue, blood and liver
at rates δTT , δTB , δTL respectively. In our model tyrosine can be transferred between the tissue and
blood compartments (rate α4, partition coefficient µ4) and between the blood and the liver (rate
α1, partition coefficient µ1).
• Once within the liver, tyrosine conversion to hydroxyphenyl pyruvic acid (HPPA, Hp) is thought
to be controlled by the enzyme tyrosine aminotransferase (TAT, A) at rate k−1; and is reversible at
rate k1 that is independent of TAT. The turnover of the enzyme TAT is assumed to be independent
of the other components of the model, being produced, for simplicity, at a constant rate (TA).
HPPA and TAT are assumed to decay naturally at rates δp and δA respectively.
• 4-hydroxyphenylpyruvate dioxygenase (HPPD, H0) is produced in the liver (at a background rate
of B0) where it catalyzes, but is not depleted by, the conversion of HPPA (rate δH ) to the down-
stream by-product homogentistic acid (R). HPPD and Homogenestic Acid decay at rates δo and
δS respectively.
• The HPPD inhibitor is administered directly into the blood (IB, for the purpose of this paper
we will not consider explicitly inhibitor plasma binding) and can transfer (at rate α3, partition
coefficient µ3) to the tissue (IT ) and (at rate α2, partition coefficient µ2) to the liver (IL). Once
within the liver the HPPD inhibitor forms a complex (C) with HPPD preventing it metabolyzing
HPPA to homogentistic acid. The complex is formed at rate k2 (that is reversible (rate k−2)) and
is assumed to decay at rate δC.
Thus the equations representing the eleven variables are:
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FIG. 2. A schematic depicting the degradation pathway of tyrosine and its inhibition via a HPPD inhibitor. Once tyrosine is within
the liver it is aided in its break down to HPPA by the enzyme TAT. HPPD then catalyzes its further breakdown to homogentistic
acid. HPPD inhibitors form a complex with HPPD within the liver inhibiting HPPD’s ability to catalyze the breakdown of tyrosine
into its downstream products.
VT
dTT
dt
= T0−α4 (TT −µ4TB)−VTδTT TT , (2.1a)
VB
dTB
dt
= α1 (TL−µ1TB)+α4 (TT −µ4TB)−VBδTBTB, (2.1b)
VL
dTL
dt
= T1−α1 (TL−µ1TB)+VLk1HP−VLk−1ATL−VLδTLTL, (2.1c)
VL
dHP
dt
= −VLk1HP+VLk−1ATL−VLδPHP−VLδHHOHP, (2.1d)
VL
dHO
dt
= B0−VLk2HOIL+VLk−2C−VLδOHO, (2.1e)
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VL
dR
dt
= VLδHHOHP−VLδRR, (2.1f)
VL
dA
dt
= A0−VLδAA, (2.1g)
VL
dC
dt
= VLk2HOIL−VLk−2C−VLδCC, (2.1h)
VT
dIT
dt
= α3 (µ3IB− IT )−VTδIT IT . (2.1i)
VB
dIB
dt
= α2 (IL−µ2IB)−α3 (µ3IB− IT )−VBδIB IB, (2.1j)
VL
dIL
dt
= −α2 (IL−µ2IB)−VLk2HOIL+VLk−2C−VLδIL IL, (2.1k)
To close this system a set of initial conditions are needed. We assume that the inhibitor is adminis-
tered as a single bolus dose, concentration I0, into the blood at t = 0, so that the non-inhibitor variables
will be at homeostatic levels. We note that I0 is the initial value of available inhibitor, based on the
assumption that inhibitor binding with plasma is rapid in comparison to transfer to the liver and tissue.
Due to feeding pattern influencing the source term T1 the initial conditions are to some extent arbitrary.
However, in the simulations and analysis to follow we assume, as a first approximation, that T1 is con-
stant (e.g. its mean concentration), and that initially the non-inhibitor related variables are in a state of
equilibrium. In the absence of the inhibitor, the steady-state for HPPD can be independently determined
(HO = B0/VLδO), which means that equations (2.1a)-(2.1d) form a linear system for the steady-state
concentrations of tyrosine and HPPA; due to their somewhat unwieldy form we denote them here using
a superscript SS and omit details of T SSB and H
SS
P for brevity; leading order dimensionless expressions
for T SSB and H
SS
P for the biologically relevant case of VB/VT ≪ 1 are presented in Section 3. The initial
conditions are thus
TT =
α4µ4T
SS
B +T0
VTδTT +α4
, TB = T
SS
B , TL =
HSSP (B0δH +VLδO(δP+ k1))
VLASSδOk−1
, HP = H
SS
P ,
HO = H
SS
O =
B0
VLδO
, R = δHB0H
SS
P
δOδR
, A = ASS = A0
δAVL
, (2.1l)
C = 0, IL = 0, IB = I0, IT = 0, (2.1m)
at t = 0. We note that from (2.1g) these initial conditions imply A ≡ ASS for all time and we henceforth
omit the differential equation of A (which corresponds to TAT concentration) in future discussions.
2.1 Parameter sizes and non-dimensionalisation
Table 2 lists all of the parameters in the proposed model. Though estimates for certain parameters are
readily available (e.g. liver, blood and tissue volumes for various animals, see Brown et al. (1997)),
others can not be obtained directly from the current experimental literature. The time-course data for a
single oral dose scenario in the rat shown in Figure 7 indicates that tyrosine concentrations increase 20-
30 fold over a 24 hour period, returning to homeostatic concentrations after about 3 days. Though these
data reveal the approximate timescales of events, it is not clear how this informs the model parameters.
Amongst the outcomes of the timescale analysis in Section 3 is to establish precisely which parameters
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Parameter Description Unit
α1 Tyrosine mass exchange rate between liver and blood LS
−1
α2 Inhibitor mass exchange rate conversion between liver and blood LS
−1
α3 Inhibitor mass exchange rate conversion between tissue and blood LS
−1
α4 Tyrosine mass exchange rate conversion between tissue and blood LS
−1
µ1 Tyrosine partition coefficient between blood and liver none
µ2 Inhibitor partition coefficient between blood and liver none
µ3 Inhibitor partition coefficient between blood and tissue none
µ4 Tyrosine partition coefficient between blood and tissue none
δC Decay rate constant of HPPD/inhibitor complex S
−1
δIB Decay rate constant of inhibitor in blood S
−1
δIL Decay rate constant of inhibitor in liver S
−1
δIT Decay rate constant of inhibitor in tissue S
−1
δA Decay rate constant of TAT S
−1
δO Decay rate constant of HPPD S
−1
δP Decay rate constant of HPPA S
−1
δH Breakdown of HPPA to HG acid M
−1 S−1
δR Decay rate constant of homogentistic acid S
−1
δTB Decay rate constant of tyrosine in blood S
−1
δTL Decay rate constant of tyrosine in liver S
−1
δTT Decay rate constant of tyrosine in tissue S
−1
A0 Maximal rate of TAT production MLS
−1
B0 Background production of HPPD MLS
−1
T0 Production of tyrosine in tissue MLS
−1
T1 Tyrosine intake rate in liver from diet MLS
−1
VB Volume of blood L
VL Volume of liver L
VT Volume of tissue L
k1 Formation of tyrosine from HPPA S
−1
k−1 Breakdown of tyrosine to HPPA M
−1 S−1
k2 “on rate” for HPPD/inhibitor binding MS
−1
k−2 “off rate” for HPPD/inhibitor S
−1
I0 Initial bolus inhibitor dose, IB(0) M
Table 2. Parameters, definitions and units. In the units column, M stands for molar, L for liters and S for seconds.
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can be reliably estimated using this data for rats. In order to do this analysis we non-dimensionalise the
system of equations (2.1a)-(2.1m) in such a way that the magnitude of new dimensionless parameters
are all expressed in terms of a small parameter, ε , defined as
ε = VBVT
, (2.2)
which is the volume ratio of the blood and tissue compartments; for the rat ε =VB/VT ≈ 0.04, and
VB/VL ≈ 2 = O(1) (see Brown et al. (1997)). As many of the parameters are unknown, we will instead
make informed estimates on the order of magnitude of the dimensionless versions. These estimates are
broadly based on the fact that components of the model clearly operate on different timescales; i.e.,
we expect that the reactions are generally fast (equilibration over O(seconds-minutes)), circulation and
compartmental exchange of tyrosine and inhibitor are not so fast (O(10 minutes-hours)) and clearance
and recovery rates will be relatively slow (O(10 hours-days), as suggested by the time-course data.
Further to this, the magnitude of parameters are chosen so that features in the data for the rat can
be reliably reproduced, namely that (1) blood tyrosine increases by an order of magnitude (a factor
of O(1/ε)) due to the inhibitor, (2) the maximum tyrosine concentration is independent of inhibitor
dose (within the range used in the experiments) and (3) the sources of tyrosine from the diet and from
production in tissue are at about the same concentration. It turns out that imposing these constraints
narrows down significantly the possible magnitudes of the dimensionless parameters in the model.
The experimental time-course data available (Figure 7) suggests that the inhibitor and its effects
occur over a number of hours and we rescale time to this long-time scale, using
t = t̂
δIB
,
where t̂ is the dimensionless time variable. From the inhibitor clearance rate, estimated to be about
1.5day−1 (see Figure 7), then t̂ = 1 represents about 16 hours. At homeostasis, the tyrosine concentration
is expected to be of the same order of magnitude throughout the body (unfortunately measurements are
only available for the aqueous humor of the rat, see Lock et al. (1996)). We scale tyrosine, HPPD
and homogentistic acid with the scaling parameter T∗ = T0/δTTVT , which is the steady tissue tyrosine
concentration in the absence of exchange in the blood. We scale HPPD and HPPD-drug complex with
the homeostatic HPPD concentration, namely HSSO = B0/δ0VL. In single dose oral exposure experiments
(see Figure 7), assuming rapid absorption, a typical quantity of inhibitor is about 1 mg/kg, thereby for
a 0.3 kg rat, this represents an initial blood concentration of IB(0) = I‡0 ≈ 0.3/(MIVB)M, where MI
is the mass per mole of inhibitor; this is in fact an upper bound of available inhibitor I0 because, as
noted earlier, we are not accounting for inhibitor plasma binding. Though I0 or I
‡
0 are natural scaling
parameters for inhibitor, we will instead scale Ii with H
SS
O so that the dimensionless quantity Ii/HO is
the molar ratio between available inhibitor and HPPD. The system is thus scaled using
Ti = T
∗ T̂i, HP = T
∗ ĤP, R = T
∗ R̂, HO = H
SS
O ĤO, C = H
SS
O Ĉ, Ii = H
SS
O Îi, (2.3)
where the hatted quantities are the dimensionless variables and i ∈ {T,B,L}.
We can infer from the experimental time-course data (again see Figure 7) that recovery from in-
hibitor intake takes about 2-3 days, which suggests that the inhibitor metabolism/decay and the turnover
of HPPD and tyrosine operate on an t̂ = O(1) timescale. Blood circulation occurs on a timescale of
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O(minutes) and we assume that the blood-organ mass exchange parameters are of O(1/ε) in size. Rel-
ative to these processes, chemical reactions are expected to occur much faster. Due to the assumed
rapidity of the two way tyrosine-HPPA reaction, tyrosine intake rate from the diet must be O(1/ε2) in
order for liver tyrosine concentration to be the same order as the blood and tissue. We assume that the
tyrosine-HPPA reaction equilibrates in a timescale of O(ε2) (in a about a minute) and likewise assume
HPPA conversion to homogentisic acid occurs at about the same rate; hence the corresponding parame-
ters are assumed to be O(1/ε2). Due to the high affinities between the inhibitor and HPPD we assume
this is the most rapid reaction, occurring at an O(1/ε3) rate (i.e. reaction saturates in a timescale of
about a second); we note that the inhibitor-HPPD complex is relatively stable and the reverse reaction
is much slower. The greater volume of tissue means that it acts as a significant sink to the inhibitor; in
order to get sufficient inhibitor into the liver, so that the maximum tyrosine is insensitive to the dose, we
require the initial blood concentration to be O(1/ε), this means on equilibration the inhibitor concentra-
tion is O(1) in the liver as required for it to be most effective. On this basis we define the dimensionless
parameters as follows,
1
ε2
{k̂1, k̂−1, δ̂H , δ̂R} = 1δIB {k1, k−1ASS, δHHSSO , δR} , (2.4)
1
ε {α̂1, α̂2, α̂3, α̂4} = 1VT δIB {α1, α2, α3, α4} (2.5){δ̂TT , δ̂TB , δ̂TL , δ̂P, δ̂IT , δ̂IL , δ̂O, k̂−2} = 1δIB {δTT , δTB , δTL , δP, δIT , δIL , δO, k−2} (2.6)
k̂2
ε3
= k2H
SS
O
δIB
,
S1
ε2
= T1
δIBVLT
∗ , ν =
VB
VL
, θ = I0
HSSO
. (2.7)
We note that the only dimensionless parameter that has an explicit dependency on the concentration of
TAT (ASS) is k̂−1; increasing this parameter is the equivalent to raising TAT. It is thought that the HPPD-
inhibitor complex is stable so that the breakdown to its components is expected to occur very slowly;
the choice of scaling k−2 is such that it is the largest order of magnitude to be visible in the analysis of
Section 3, but has no meaningful effects on the dynamics (i.e. setting k̂−2 = 0 will make no difference
to the results).
Applying all these scalings on the variables and parameters leads to the system of dimensionless
equations (the hats have been dropped from now on)
dTT
dt
= δTT (1−TT ) + α4(µ4TB−TT ), (2.8a)
ε
dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTB TB, (2.8b)
ε2
dTL
dt
= S1 − ε α1ν (TL−µ1TB) + k1HP − k−1TL − ε2 δTL TL, (2.8c)
ε2
dHP
dt
= − k1HP + k−1TL − δHHOHP − ε
2 δPHP, (2.8d)
ε3
dHO
dt
= ε3 δO(1−HO) − k2HO IL + ε3 k−2C, (2.8e)
ε2
dR
dt
= δHHOHP − δRR, (2.8f)
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ε3
dC
dt
= k2HO IL − ε
3 k−2C − ε
3 δCC, (2.8g)
dIT
dt
= −α3 (IT −µ3 IB) − δIT IT , (2.8h)
ε
dIB
dt
= α2 (IL−µ2 IB) + α3 (IT −µ3IB) − ε IB, (2.8i)
ε3
dIL
dt
= − ε2α2 ν (IL−µ2 IB) − k2HO IL + ε3 k−2C − ε3 δIL IL. (2.8j)
2.2 Initial conditions
The dimensionless form of the initial conditions (2.1) are
TT =
α4µ4T
SS
B + εδTT
α4+ εδTT
, TB = T
SS
B , TL =
HSSP (δH + k1+ ε2δP)
k−1
, HP = H
SS
P ,
HO = 1, R =
δH
δR
HSSP , C = 0, IL = 0, IB = θ , IT = 0,
at t = 0, omitting the somewhat cumbersome form of T SSB and H
SS
P as before. Rats receive the inhibitor
via a food bolus (which must be absorbed from the gut into the bloodstream) or intravenously. Clearly
there will be some form of delay in the former, but in the latter this represents an instantaneous intro-
duction to IB. The scalings imply that
Scaled total mass/mole of inhibitor = ITε + IB +
IL
ν . (2.9)
2.3 Simulations
In preparation for our time scale analysis, we consider a “typical” evolution first. Figure 3 shows the
evolution of each of the ten dimensionless variables; here all the parameters are set to one except ε =
0.04. The system (2.8a)-(2.2) was solved using Rosenbrock’s method implemented in the mathematics
package Maple 17. The initial blood concentration of inhibitor is set at IB(0)= 1/ε = 25, corresponding
to the “high” dose used in the experiments discussed in Section 4. For the remaining variables, we used
the pretreatment steady-state concentrations (numerically calculated), namely TT (0) ≈ 1.30,TB(0) ≈
1.60,TL(0) ≈ 1.96,HP(0) ≈ 0.98,HO(0) = 1 and R(0) ≈ 0.98, and set IT (0) = IL(0) =C(0) = 0.
We observe that the inhibitor rapidly infiltrates the liver (bottom right) and drives down HPPD (top
right) from 1 to about 10−5; the events leading to this are not clearly seen in the plot, but are discussed
in detail in the first part of Section 3. With HPPD concentrations being negligible, tyrosine (top left)
builds up fairly rapidly in the liver, then in the blood and, over a longer timescale, in the tissue, all
peaking at around the same time at t ≈ 2 (about 32 hours after the initial dose). Despite the rise in
HPPA, homogentistic acid drops to very low concentrations. Following this initial phase, the inhibitor
spreads evenly throughout the body and decays allowing HPPD to slowly recover. This continues to
about t ≈ 2 when the inhibitor concentration in the liver collapses as HPPD has built up sufficiently to
exhaust supply; the latter eventually drives down HPPA and consequently tyrosine recovers to pretreated
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FIG. 3. Plots of the evolution of the dimensionless variables. For the tyrosine (top left) and inhibitor (bottom right), the concen-
trations in the blood (solid), tissue (dashed) and liver (dotted) are shown. Top right shows the evolution of HPPD (solid) and the
complex (dashed) and bottom left shows HPPA (solid) and homogentistic acid (dash). We note from the scalings in Section 2.1,
t = 1 represents about 16 hours. All dimensionless parameters are set to unity except ε = 0.04.
concentrations around t ≈ 3 (about 2 days). Qualitatively speaking, the pattern of behaviour shown in
Figure 3 is as to be expected. It is noteworthy however, that the model predicts that homogentistic acid
(bottom left) has recovered to pretreated concentrations around t = 2, reflecting a return to near normal
conditions in the liver, despite the animal still being in a high state of tyrosinaemia.
The effect of inhibitor dose on the maximum blood tyrosine (TB, measurable) and minimum HPPD
(HO) concentrations are shown in Figure 4. The figures appears to show that there is a threshold con-
centration, say θ = θ∗, between an effective and ineffective dose. When θ < θ∗ there is insufficient
inhibitor reaching the liver to drive down HPPD to negligible concentrations, consequently, there is a
very little rise in tyrosine. For θ > θ∗, HPPD is exhausted in the liver allowing HPPA, and consequently
tyrosine, to rise significantly to a new equilibrium. As the dose increases, HPPD concentrations decrease
further (in fact the asymptotic analysis of Section 3 predicts HOmin ∼ 1/θ ), which means it takes longer
to recover and hence allowing more time for tyrosine to build in the blood and tissues. The estimated
quantities indicated by the dashed line are discussed in Section 3.2.
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FIG. 4. Figures showing the effect of inhibitor dose on maximum blood tyrosine concentration (left) and on minimum HPPD con-
centration (right). The ⧫ corresponds to θ = 1/ε (orΘ = 1 in Section 3.1) and the vertical dotted line corresponds to θ = θ∗ (here
θ∗ = 2) marking the switch between ineffective and effective inhibitor dose. The dashed lines are the analytical approximations
to these quantities derived in Section 3, and discussed in Section 3.2, specifically that on the left is equation (3.38) and on the right
(3.40); note that those for the minimum HPPD are almost superimposed on the numerical solution. All dimensionless parameters
are set to unity except for ε = 0.04 and IB(0) = 1/ε = 25.
3. Time-scale analysis
In this Section we exploit the fact the ε≪ 1 to identify key timescales that the model operates over and
the processes that are predicted to occur within each timescale. Examination of the data, presented in
Section 4, reveals that the maximum tyrosine concentration appears to be about the same for each of
the inhibitor doses, which suggests that there is a saturation effect in which the inhibitor has effectively
taken out the HPPD, leading to tyrosine to equilibrate to a new, HPPD independent, concentration.
Hence we expect for this case that the initial inhibitor concentrations are large compared to the HPPD
concentrations and therefore assume IB(0) = O(1/ε). With regards to the data, this case is of most
interest and hence is analysed in detail in Section 3.1. However, as is observed in Figure 4, the rapid
switch, in response to the inhibitor seems to occur when IB(0) = O(1); the analysis for this case is
summarised in Section 3.2, where in particular we determine this critical dose in terms of the model
parameters.
3.1 Large initial dose IB(0) = O(1/ε)
As stated above, in this Section we analyse the case that the initial inhibitor concentrations are large
compared to the HPPD concentrations and hence set
IB(0) = θ = Θε (3.1)
where constantΘ = O(1); the initial conditions are to leading order,
TT (0) ∼ S1α1α4 µ4 (δH + k1) + δH δTT k−1 (α1µ1+α4µ4)δH k−1 (α1µ1α4 + δTT (α µ1 + α4 µ4)) = T SST0 (3.2)
TB(0) ∼ S1α1 (δH + k1)(α4+δTT ) + δH δTT k−1α4δH k−1(α1µ1α4 + δTT (α µ1 + α4 µ4)) = T SSB0 (3.3)
TL(0) ∼ S1(δH + k1)δH k−1 = T SSL0 , HP(0) ∼ S1δH = HSSP0 (3.4)
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HO(0) = 1 R(0) ∼ S1δR = RSS0 (3.5)
C(0) = 0, IT (0) = 0, IB(0) = Θε , IL(0) = 0. (3.6)
A concentration of IB(0) = O(1/ε) means that should the inhibitor instantaneously disperse around
the body then (2.9) implies that Ii = O(1) throughout. In the course of the analysis we identify sixteen
timescales in total, a few describe the main dynamics of the system, whilst the rest are rapid transitional
timescales linking the important ones. In the interest of brevity, we summarise the main results within
these main timescales in Sections 3.1.1-3.1.6, whereby full details of the asymptotic analysis (for all
sixteen timescales) is given in Appendix A. A brief commentary of the sequence of events is presented
in Table 3, in which estimates to real time and molecular concentrations are given to help contextualise
the analysis.
In the forthcoming analysis, it is customary to indicate the rescaled variables for each of the timescales
with some form of notation that uniquely identifies a variable belonging to a particular timescale. In the
interest of brevity, this has not been done here. The solutions and discussion on the variables are for the
relevant timescale only, unless otherwise stated. The leading order terms for each timescale are indi-
cated with a subscript 0. The term “negligible” refers to variables being o(1) the size of the pretreated
state; this being particularly relevant for HPPD.
3.1.1 Timescale 1: t = O(ε3) . Initially we look at the short timescale (t ↦ ε3 t) where we introduce
the scalings
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ HO, (3.7a)
R ↦ R, C ↦ εC, IT ↦ ε
2 IT , IB ↦
IB
ε , IL ↦ ε IL. (3.7b)
Applying this to the nondimensional system of equations (2.8), we obtain the leading order solutions
TT0 = T
SS
T0 , TB0 = T
SS
B0 , TL0 = T
SS
L0 , HP0 = H
SS
P0 , (3.7c)
HO0 = 1, R0 = R
SS
0 , IB0 = Θ . (3.7d)
For the remaining variables we note that d(C0+ IL0)/dt = α2νΘ , hence at leading order
IT0 = α3 µ3Θ t, IL0 =
ν α2 µ2Θ
k2
(1 − e−k2 t) , (3.7e)
C0 = ν α2 µ2Θ t −
ν α2 µ2Θ
k2
(1 − e−k2 t) . (3.7f)
On this initial timescale the inhibitor infiltrates the liver and equilibrates to a level IL ∼ ε να2µ2Θ/k2,
which is a balance between inhibitor influx and inhibitor reaction with HPPD. Negligible, i.e. o(1),
concentrations of HPPD are lost and liver tyrosine produced. The inhibitor is infiltrating tissue at a low,
O(ε), level and the linear accumulation of IT0 and C0 leads to a change in balance at t = O(1/ε).
3.1.2 Timescale 2: t = O(ε2) . From the large time behaviour of the initial timescale we rescale
time such that t ↦ ε2 t and the variables representing the complex formed from HPPA and HPPD and
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Timescale 1: t =O(ε3), O(4) seconds
The inhibitor diffuses into the liver and tissue from the blood. Liver concentrations are small
though, i.e. it rises to O(ε)≈ 0.01µmole/ml (tissue concentrations much smaller).
Timescale 2: t =O(ε2), O(90) seconds
During this timescale HPPD drops rapidly to negligible concentrations. The liver concentrations
of inhibitor are still O(ε), but this is due to the rapid reaction with HPPD; the inhibitor level
eventually rises over a series of intermediate timescales.
Timescale 6: t = ε2η3+O(ε2), 3+ minutes
Difficult to be precise on the time in real terms due to the parameters in η3. However, the
inhibitor level in the liver has built up to O(1)≈ 0.2µmole/ml. HPPD concentrations are O(ε2)≈
0.1% that of the untreated level and homogentistic acid also rockets down to about 0.1% at the
same time.
Timescale 9: t =O(ε), O(1) hour
HPPD is at a minimum level of O(ε4)≈ 0.0001% of the healthy level and consequently HPPA is
about 20× its pretreated state. The consequential accumulation of tyrosine in the liver has driven
blood concentration to increase by an order of magnitude. However, it has yet to reach its peak
due to movement into tissue. The inhibitor is being soaked up by the tissue and its concentration
will eventually equilibrate throughout the rat’s body,
Timescale 11: t =O(1), O(1) day
The tyrosine in the tissue becomes saturated forcing blood concentration to rise further to reach
a peak. This continues whilst there is sufficient inhibitor in the liver to maintain negligible
HPPD, however, their equilibrated concentration is decaying exponentially. This continues on
through Timescale 12 (where inhibitor has dropped by an order of magnitude) and HPPD begins
to increase.
Timescale 15: t = η12+η13+ O(1), 3+ days
Following a rapid collapse in liver tyrosine to near normal concentrations over Timescales 13 and
14, this timescale represents a recovery period throughout the animal. Here, tyrosine concentra-
tions in blood and tissue are in decline (exponentially), being metabolised by HPPD following
absorption into the liver. Tyrosine concentration reach their pretreated value in Timescale 16.
Table 3. A list of the major timescales of events following a “large” bolus dose (i.e. θ = O(1/ε)) of inhibitor. The estimated
dimensional values for the timescales and concentrations are included to ease contextualisation. The analytical results for each
of these timescales are summarised in Sections 3.1.1-3.1.6 and full details, including the intermediate timescales, are given in
Appendix A.
the inhibitor in tissue such that
C ↦ C, IT ↦ ε IT . (3.8a)
When applied to equations (2.8), this leaves the leading order solutions for tyrosine and the inhibitor in
the tissue and blood unchanged
TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , IT0 = α3µ3Θ t, (3.8b)
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while the solutions for the complex, HPPD and its inhibitor in the liver are now
C0 = να2µ2Θ t, HO0 = 1 − να2µ2Θ t, IL0 =
να2µ2Θ
k2(1−Θνα2µ2 t) . (3.8c)
The remaining variables are the solutions of differential equations that seem not to be analytically solv-
able, namely
dTL0
dt
= S1 + k1HP0 − k−1TL0 , (3.8d)
dHP0
dt
= −k1HP0 + k−1TL0 − δH (1 − να2µ2Θ t) HP0 , (3.8e)
dR0
dt
= δH (1 − να2µ2Θ t) HP0 − δRR0. (3.8f)
On this timescale we find that HPPD concentrations (HO0 ) “collapse” and liver inhibitor concentrations
(IL0 ) “explode” in finite time, specifically as t → η3(ε)−, where η3(0) = 1/ν α2 µ2Θ , whilst all other
variables maintain their order.
3.1.3 Timescale 6: t = ε2η3(ε)+O(ε2) . After several rapid transitional timescales, we now move
to Timescale 6 where time is rescaled such that t ↦ ε2η3(ε) + ε2 t. Most variables retain the scalings
of timescale two except those for HPPA and the inhibitor in liver which are rescaled such that
HO ↦ ε
3HO, IL ↦ IL. (3.9a)
At leading order the following solutions remain as they were at timescale two
TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , (3.9b)
whilst
C0 = 1, (3.9c)
and
IT0 =
α3µ3
α2µ2 ν + α3µ3Θ t, IL0 = να2µ2Θ t, HO0 =
δO + k−2
k2 ν α2 µ2Θ t
, R0 = R
[2]
0 (η3)e−δR t , (3.9d)
HP0 = H
[2]
P0 (η3) + k−1 S1k1+ k−1 t + (1− e−(k1+k−1) t )k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) , (3.9e)
TL0 = T
[2]
L0 (η3) + k1 S1k1+ k−1 t − (1− e−(k1+k−1) t )k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) , (3.9f)
where the superscript [2] refers to the solution in Timescale 2. The inhibitor is infiltrating into the
tissue, whilst the inhibitor in the liver (IL0 ), HPPA (HP0 ) and liver tyrosine concentration (TL0 ) increases
and HPPD (HO0 ) concentration decreases. Blood tyrosine is relatively unchanged (TB0 ), however, the
homogentisic acid (R) and downstream products (P) drop rapidly.
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3.1.4 Timescale 9: t = O(ε) . For this timescale we write t ↦ ε t and find that, since Timescale 6,
the following scalings have changed
TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
4HO, (3.10a)
R ↦ ε3R, IT ↦ IT , IL ↦
IL
ε . (3.10b)
The leading order solution for the complex remains as it was at Timescale 6
C0 = 1. (3.10c)
The equations for tyrosine and HPPA decouple and are solutions to linear second order differential
equations, given by
TB0 =
S1
να4µ4 (1 + E+T (t) − E−T (t)) , (3.10d)
TT0 = T
SS
T0 +
S1
ν ( t − (E+T (0)−E+T (t)) + (E−T (0)−E−T (t))) , (3.10e)
TL0 =
S1 (α1µ1+α4µ4)
να1α4µ4 +
S1
να1α4µ4 (ω−αµ E+T (t) + ω+αµ E−T (t)) , (3.10f)
HP0 =
S1 k1 (α1µ1+α4µ4)
k−1να1α4µ4
+
S1 k1
k−1να1α4µ4
(ω−αµ E+T (t) + ω+αµ E−T (t)) , (3.10g)
where E±T (t) = ω+ω−eω±t/ω±(ω+−ω−) and ω±αµ = α1µ1+α4µ4+ω±, where
ω± = −12 ( k1να1k1+ k−1 + α1µ1+α4µ4) ± 12 (( k1να1k1+ k−1 + α1µ1−α4µ4)2 + 4α1µ1α4µ4)1/2; (3.10h)
noting that ω− <ω+ < 0 and hence E±T (t)→ 0 as t→∞. These results show that tyrosine concentration
is rising everywhere, however, the seepage into tissue means that an equilibrium is eventually reached
in the liver and blood, namely
TB0 ∼
S1
να4µ4 = T
[9]
B∞ , TL0 ∼
S1 (α1µ1+α4µ4)
να1α4µ4 = T
[9]
L∞ (3.10i)
We note, these equilibrium values are a temporary maximum level, which are superseded when tyrosine
saturates in the tissue (Timescale 11). This indicates that there is a two stage “jumping” of tyrosine
concentration; though not observable in the data, or in the simulations in Figure 3, they do become
apparent for smaller ε (Figure 5, top right).
Similarly to the tyrosine equations, the equations for the inhibitor also decouple into a linear second
order differential equations, namely
IL0 = Θ ν α2 µ2 (E+I (t)−E−I (t)), IB0 = Θ (ρ+αµE−I (t)−ρ−αµE+I (t)) (3.10j)
IT0 = Θ (1 + ρ−αµ(ρ+αµ +να2)E+I (t) − ρ+αµ(ρ−αµ +να2)E−I (t)) (3.10k)
where E±I (t) = eρ±t/(ρ+−ρ−) and ρ±αµ = α2µ2+α3µ3+ρ±, where
ρ ± = − (α3 µ3 + α2 (µ2+ν))2 ± 12 (α3µ3 + α2 (µ2+ν))2 − 4ν α2α3 µ3)1/2 , (3.10l)
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noting that ρ− < ρ+ < 0 and hence E±I (t)→ 0 as t →∞. For brevity, we express the leading solutions
of the remaining variables as follows
HO0 =
δO+ k−2
k2
1
IL0
, R0 =
δH(δO+ k−2)
δR k2
TL0
IL0
. (3.10m)
Inhibitor concentration in the blood (IB0 ) and eventually in the liver (IL0 ) declines as it infiltrates into
tissue acting as a inhibitor sink, rising to a maximum level of IT0 ∼Θ . As liver inhibitor concentration
decline, HPPD and homogentisic acid start to rise.
3.1.5 Timescale 11: t = O(1). On this timescale the following new scalings have been introduced
since Timescale 9 to reflect that IB = O(1) and is no longer large:
TT ↦
TT
ε , HO ↦ ε
3HO, R ↦ ε
2R, IB ↦ IB, IL ↦ IL. (3.11)
At leading order, the equations representing the inhibitor can be solved to give
IT0 = Θ e
−δIt t , IB0 =
Θ
µ3 e
−δIt t , IL0 =
Θ µ2
µ3 e
−δIt t , (3.12)
and those for the complex concentration leads and
C0 =
δO
δC
+ (1− δO
δC
) e−δC t , (3.13)
and for HPPD,
HO0 =
µ3
k2µ2Θ
(δO (1+ k−2δC )+(1− δOδC ) e−δC t) eδIT t . (3.14)
The solutions for tyrosine and HPPA are
TT0 =
S1
ν δTT
(1 − e−δTT t) , (3.15)
TB0 =
S1
ν α4 µ4 +
S1
ν δTT µ4
(1 − e−δTT t) , (3.16)
TL0 =
S1 (α1µ1+α4µ4)
να1α4µ4 +
S1 µ1
νδTT µ4
(1 − e−δTT t) , (3.17)
HP0 =
S1 k−1 (α1µ1+α4µ4)
k1να1α4µ4
+
S1 k−1µ1
k1νδTT µ4
(1 − e−δTT t) . (3.18)
Finally, we obtain for the homogentisic acid R0 = δHHOHP/δR.
Reflecting on these results, we note that tissue tyrosine concentration is matching that of the blood
and liver and leads to further build up of tyrosine throughout; HPPA suitably adjusts to this build up.
Inhibitor has equilibrated and is decaying naturally (note the vast majority of the inhibitor is in tissue
and its kinetics dominate the overall decay rate). HPPD and homogentisic acid are increasing, but
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concentrations are still very small, and the complex adjusts to a new equilibrium as HPPD production
and the complex’s natural decay balance out. The large time solutions are
TT0 ∼
S1
ν δTT
= T [11]T∞ , TL0 ∼ S1νµ4 ( µ1δTT + µ1α4 + µ4α1 ) = T [11]L∞ , (3.19)
HP0 ∼
S1 k−1
k1νµ4
( µ1
δTT
+
µ1
α4 +
µ4
α1 ) = H[11]P∞ , C0 = δOδC , (3.20)
and, of particular interest, is the leading order maximum blood tyrosine level, namely
TB0 ∼
S1
ν µ4 ( 1α4 + 1δTT ) = T [11]B∞ , (3.21)
as t →∞, where we note in particular its independence to the initial inhibitor concentration Θ . These
expansions become invalid when IL0 = O(1/ε), i.e. when t = δ−1IT ln(1/ε)+O(1).
Numerical simulations aimed at testing the accuracy of the approximations revealed that the large
time value for TB0 turns out not to predict well the peak of blood tyrosine level using ε ≈ 0.04 (about
40-50% error); see Figure 4, particularly for θ > θ∗. When t ∼ δ−1IT ln(1/ε), we have to leading order
TB ∼ (T [11]B0 +O(εδTT /δIT ))/ε; since the parameters are set to one, the error is about −1 of the predicted
maximum, T [11]B0 /ε . However, analysis of the correction term, using the expansions TB ∼ TB0+εTB1 etc.,
reveals that TB1 → T
[11]
B1∞
, where
T [11]B1∞ ∼− S1(α4+δTT )((δTLk1+δPk−1)(α1µ1α4+δTT (α1µ1+α4µ4))+ k1δTBνα1(α4+δTT ))k1ν2δ 2TTα1α24µ24 + 1µ4 ,
(3.22)
as t →∞. Here, T [11]B1∞ consists of several products of sums, so if, for example, all parameters are set to
one, then T [11]B1∞ ≈−15 and makes a significant contribution to the estimated maximum value of TB when
the modestly small ε ≈ 0.04 is used. However, in the limit ε → 0 this issue is not a problem (see Figure
5, top right).
Much of the data of blood tyrosine and inhibitor concentrations correspond to this timescale. The
exponential decay of IB0 predicted in equation (3.12) will form the basis for fitting with the inhibitor
data, whilst a modified form of (3.16) will be used to fit part of the blood tyrosine data.
3.1.6 Timescale 15: t = η12(ε) + η13(ε) + O(1) . Where η12(ε) = δ−1IT ln(1/ε) and η13(ε) =
O(1) defined so that η13(0) = δ−1IT ln[Θ ν α2 µ2α3 δIT /δO (α2 µ2α3+ δIT (α2µ2+α3µ3))]. Timescale
12 sees the continuation of inhibitor decline and slow HPPD recovery for an O(1) time, until there
is a rather sudden collapse of inhibitor concentration in the liver, namely O(ε) → O(ε3), as HPPD
production rate finally overtakes inhibitor absorption from the blood reservoir and recovers to near its
pretreated level (Timescales 13 and 14). Furthermore, the rapid rise in HPPD leads to a rapid collapse
in liver tyrosine, causing a rapid drop in blood tyrosine from its peak (T [11]B∞ ) to a new level (T [14]B∞ ,
defined below), though still much higher than the pretreated concentration due to the tyrosine in tissue
acting as the main reservoir. We note further, that since the initial inhibitor concentration θ =Θ/ε , with
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Θ =O(1), is sufficient to eliminate HPPD, the only other significant effect it has is in delaying the onset
of Timescale 13 and consequently the current one.
Writing t ↦ η12(ε) + η13(ε) + t, the following rescalings have changed since Timescale 11,
TL ↦ TL, HP ↦ HP, HO ↦ HO, IL ↦ ε
3 IL (3.23)
We find that blood and tissue tyrosine are dropping according to
TT0 =
S1
νδTT
e−Ω
[15]
T t , TB0 = T
[14]
B∞ e
−Ω [15]T t (3.24)
where T [14]B∞ = S1α4/νδTT (α1µ1+α4µ4) and
Ω [15]T = α1µ1α4+δTT (α1µ1+α4µ4)α1µ1+α4µ4 . (3.25)
Defining
φO(t) =Ω [15]I e−δOt −δOe−Ω [15]I t , φC(t) =Ω [15]I e−δCt −δCe−Ω [15]I t (3.26)
where Ω [15]I = (α2µ2α3 + δIT (α2µ2 +α3µ3))/(α2µ2 +α3µ3), noting that φi(t)→ 0 as t →∞, then
HPPD, HPPA, liver tyrosine and homogentisic acid return to their pretreated concentrations according
to
HO0 = 1 −
φO(t)
φO(0) , (3.27)
HP0 = H
SS
P0 +
S1 φO(t) + ν α1 µ1 φO(0)T [14]B∞ e−Ω [15]T t
δH (φO(0)−φO(t)) , (3.28)
TL0 = T
SS
L0 +
S1 k1 φ(t) + ν α1 µ1T [14]B∞ e−Ω [15]T t (φO(0)(δH + k1)−δH φO(t))
δH k−1 (φO(0) − φO(t)) , (3.29)
R0 = R
SS
0 −
δH
δR
⎛⎜⎜⎜⎝ φO(t)φO(0)HSSP0 + (1− φO(t)φO(0))
⎛⎜⎜⎜⎝S1 φO(t) + ν α1 µ1 φO(0)T
[14]
B∞ e
−Ω [15]T t
δH (φO(0)−φO(t)) ⎞⎟⎟⎟⎠
⎞⎟⎟⎟⎠ . (3.30)
The rising concentration of HPPD accelerates absorption and degradation of the inhibitor in the liver
from the blood and tissue, thus the inhibitor related variables decay
IT0 =
δO(α2µ2+α3µ3)
να2µ2α3 e
−Ω [15]I t , IB0 = δOνα2µ2 e−Ω
[15]
I t , C = δO
δC
φC(t)
φC(0) , (3.31)
IL0 =
δO e
−Ω [15]I t + k−2 δO φC(t)/δC φC(0)
k2 (1−φO(t)/φO(0)) . (3.32)
All that remains is for the blood and tissue tyrosine to return to their pretreated concentrations. This
occurs in Timescale 16, where t ↦ η12(ε) + η13(ε) + η16(ε) + t (here, η16(ε) = ln(1/ε)/Ω [15]T ) and
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both TT and TB are O(1) satisfying
TT0 = T
SS
T0 +
S1
νδTT
e−Ω
[15]
T t , TB0 = T
SS
B0 + T
[14]
B∞ e
−Ω [15]T t ; (3.33)
hence tyrosine concentration tend to the pretreated state to leading order as t →∞.
3.1.7 Comparison with numerical solutions Figure 5 shows a selection of comparisons between the
numerical solutions for the full-system and composites of the leading-order asymptotic terms. The
composite solutions are derived by adding successive timescale solutions and subtracting the common
term; although in the cases shown, most of contributions from the successive time-scales cancel each
other out. For the plots in Figure 5, the solution for blood tyrosine, T compB , complex C
comp and blood
nitisone IcompB are, in their most reduced form,
T compB = H (t[14]− t)(T SSB0 + T [9]B0 + T [11]B0 − T [9]B∞ ) + H(t− t[14])(T [14]B0 + T [16]B0 − T [14]B∞ ) , (3.34)
Ccomp = H (t[2]− t)(C[1]0 +C[2]0 −C[1]∞ )+H (t− t[2])(C[11]0 +H (t− t[14])(C[15]0 −C[11]0 )) , (3.35)
IcompB = H (t[14]− t)(I[9]B0 + I[10]B0 + I[11]B0 + I[12]B0 − I[9]B∞ − I[10]B∞ − I[11]B∞ ) + H(t− t[14]) I[15]B0 , (3.36)
where ∗[i]0 , with ∗= {TB,C, IB}, is the leading-order solution of ∗ for timescale i, ∗[i]∞ is the correspond-
ing large time limit, t[2] = ε2η3 and t[14] = η12(ε)+η13(0), and H(z) is the Heaviside step function
such that H(z) = 0 for z < 0 and H(z) = 1 for z ≥ 1. The step-functions are used as a convenient way of
eliminating the complexities in the intermediate timescales around t = t[2] and t[14], whereby the solu-
tions in intermediate timescales provide jump conditions for the composite solutions either side of them
(although the only discontinuity here is TB at t
[14]); we note that the composite solutions (3.34)-(3.36)
are asymptotically valid as ε → 0. For HPPD, HO, and liver drug concentration, IL, it is not possible to
construct a likely looking composite solution using leading order approximations, due to the tails of the
solutions for one timescale significantly encroaching on the solutions of the neighbouring ones when ε
is modestly small; we hence show results for individual timescales (open shapes) and composites of a
short sequence of timescales (solid shapes).
Formally, the asymptotic analysis only applies in the limit ε → 0, nevertheless the figures shows
that there is generally good agreement between the analytical and numerical solutions for ε = 0.04. For
C, IB and IT (not shown), the composite solutions agree very well across the entire time interval, whilst
for HO, IL and R (not shown) the approximations agree well within their own timescale. The solutions
for TB,TT ,TL and HP have similar qualitative profiles, for which only TB is shown for brevity. For the
parameter set used, there is a significant disparity around where TB reaches its maximum (as seen in
Figure 4), the reasons for which being discussed in Section 3.1.5; we note there are similar disparities
for TT ,TL and HP as well. However, as expected, the agreement can be much improved by reducing ε ,
as can be seen for ε = 0.01 case in the top right plot. We also note, that the two stage accumulation of
TB during Timescales 9 and 11 is observable in this plot.
3.2 Moderate initial dose IB(0) = O(1)
The analysis for the case IB(0) = θ = O(1) follows the same lines as that described in Section 3.1 and
we omit all the details for brevity. This analysis is motivated by the results shown in Figure 4 where
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FIG. 5. Figures comparing the numerical solutions of the full system (solid lines) with asymptotic solutions (dashed or dashed
with symbols). The top two figures compares the composite solution of TB, as given by (3.34), for the cases for ε = 0.04 (top left)
and ε = 0.01 (top right), respectively. Middle left compares the asymptotic and numerical solutions of HO at various timescales:
timescales 2 (◇), composite of timescales 3-8 (◆), timescale 9 (△), 10-12 (▲) and 15 (□). Middle right and bottom left show
full composite solutions of C and IB, respectively. Bottom right shows the solutions for IL at timescales 1-2 (◆), 3 (△), 9-12 (▲)
and 15 (□). All dimensionless parameters are set to unity with θ = 1/ε (orΘ = 1) and ε = 0.04.
there appears to be a critical inhibitor concentration, denoted θ∗, beyond which the inhibitor is effec-
tive at substantially reducing HPPD concentration, with a consequential rise in tyrosine concentration.
Undertaking the time-scale analysis for this case reveals that the critical time point which results in the
divergence in inhibitor effectiveness is in the third timescale (t = O(ε)) of this analysis, whereby the
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“critical concentration” is revealed, namely
θ∗ = 1ν (1 + α3 µ3α2 µ2 ) . (3.37)
A remarkable feature of this critical concentration is that it is independent of the reaction kinetics at
leading order and is governed by the relative volumes of blood and liver (ν) and the transport and parti-
tioning parameters of the inhibitor across the liver/blood/tissue phases. This is actually due, according
to the model, to the reactions being so rapid that the limiting factor in inhibitor effectiveness is delivery
to the liver.
Further to this, the analysis enables us to derive a formula for the maximum amount of tyrosine in
the blood. The details are technical and there are several cases depending on the relative sizes of various
parameter groupings; however, those that are relevant to the results shown in Figure 4 are
TBmax ∼
⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎩
α4T
SS
T0
α1µ1+α4µ4 +
1(θ∗−θ) S1α1(θ∗(δH + k1) − θδH)(α1µ1+α4µ4)k−1δH θ < θ∗,
1
ε
S1
να4µ4 θ
∗ < θ < θL,
1
ε
⎛⎜⎜⎝ S1να4µ4 + S1νδIT µ4 ⎛⎜⎜⎝1 − (1− δIT A(1,1)(θ−θL)δIT A(1,1)(θ−θL)+Ω [15]I A(θL−θ∗,θL))
δTT
δIT
⎞⎟⎟⎠ θL < θ ,
(3.38)
where A(x,y) = α2µ2 x+α3µ3 y, Ω [15]I is defined below equation (3.26), and
θL = θ
∗ (δOα3 + α2µ2α2µ2+α3µ3 ) , (3.39)
is a minor critical inhibitor concentration discussed below. We first note TBmax is continuous at θ = θL,
though curiously non-smooth, and that TBmax = T
[11]
B0 (equation (3.21)) as θ →∞, in agreement with the
analysis of θ = 1/ε . Secondly, we note that, if θL < θ∗, then only the first and third terms in (3.38) are
relevant. For the low dose case (i.e. θ < θ∗), there is a constant contribution of blood tyrosine from the
tissue phase and a θ dependant term from the liver, showing explicitly TB increases with increasing dose.
Passing through the critical inhibitor dose, for an intermediate dose concentration of θ∗ < θ < θL, HPPD
is rapidly eliminated and blood tyrosine equilibrates to ε−1S1/να4µ4 = T [9]B∞ /ε (see Section 3.1.4), at
leading order; however, by O(1) time the drug is exhausted so that the slower process of HPPD recovery
occurs unhindered allowing no further build up of tyrosine (hence TBmax is approximately constant in the
intermediate range of θ ). For θ > θL, inhibitor concentrations in the liver remain high for long enough
to maintain a low level of HPPD over an O(1) time period, thereby allowing tyrosine to further build
up in tissue beyond the T [9]B∞ /ε level, leading to a secondary rise in blood tyrosine concentration (as
observed in Timescale 11, Section 3.1.5).
We can also deduce the minimum HPPD level from the analysis and find that
HOmin ∼
⎧⎪⎪⎪⎪⎪⎨⎪⎪⎪⎪⎪⎩
1 −
θ
θ∗
θ < θ∗,
ε3
δO+ k−2
k2 I
∗
L
θ∗ < θ ,
(3.40)
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where I∗L = (θ −θ∗) I cL , with constant I cL = να2µ2(ρ+−ρ−)−1 maxt>0(eρ+t − eρ−t) (the constants ρ±
being defined in (3.10l)). For θ < θ∗, only θ/θ∗ of inhibitor makes it into the liver and is insufficient to
totally deplete HPPD. However, for θ > θ∗, HPPD concentration drops by several orders of magnitude
and, as observed in Timescale 9 (Section 3.1.4), it is in a quasi-steady balance between production and
inhibition. We note, that the minimum HPPD concentration is highly dependent on the reaction kinetics,
unlike tyrosine, which is governed more by the mass transfer kinetics between phases.
The leading order estimates for TBmax and HOmin (dashed lines) are compared with the full solutions
(solid lines) in Figure 4. Whilst, the predicted estimate of TBmax is reasonable for θ < θ
∗, they are
fairly poor for θ > θ∗. The reason for this has already been highlighted in the discussion of Timescale
11 (Section 3.1.5) where the corrections terms are unduly large in comparison to 1/ε with ε = 0.04.
Decreasing ε improves agreement and the constant value in θ∗ < θ < θL becomes more evident. How-
ever, with ε = 0.04, the estimates for HOmin are already very good (the dashed lines are more-or-less
superimposed by the solid one).
4. Data fitting
The rat data used in the parameter fitting consists of time course measurements of the concentrations
of tyrosine and the inhibitor nitisinone in the blood, i.e. TB and IB in the model (see Appendix B for
animal experimentation details). In the experiments three different doses were investigated, namely at
0.5, 1 and 2 mg/kg; in each case, three rats (nine in total) were given the same dose and there were three
untreated rats used as control. The measurements were taken over seven days, with seven data points
taken on day 1 (t = 0,0.5,1,2,4,8,12 hours), two on day 2 (t = 24,36) and then once daily afterwards
(t = 48,72,96,120,144,168). A key feature of the experimental results is that the peak blood tyrosine
concentration is roughly the same across the three doses, which motivated the consideration of the large
dose case IB(0) = O(1/ε) in the analysis of Section 3.1.
It is possible to attempt parameter estimation by fitting the full model solutions to the available data
using various software packages, and though they often provide detailed statistical analysis of the relia-
bility of fit it is difficult to obtain insights into why some parameters are fitted more reliably than others.
Here, we will fit the data to the simpler versions of the model, motivated by the analysis of 3.1, which
helps to identify which parameters the data is able to reliably inform. The “fit” command in the gnuplot
package was used to fit to the inhibitor data and for the tyrosine data the “FME” package was im-
plemented within the programming language R; in both cases, the Levenberg-Marquardt minimisation
algorithm was used.
The asymptotic analysis of Section 3.1 showed that following an initial transient the blood inhibitor
profile in dimensional terms settles to
IB ∼
I0VB
µ3VT
e−δIT t , (4.1)
in a t = O(1) timescale (see Section 3.1.5). The predicted exponential decay agrees with the data
following a short time period after bolus ingestion. Equation (4.1) has one parameter group (θ0 =
I0VB/µ3VT ) and one free parameter (δIT ), which were fitted to raw data and to a logged version of
the raw data, from t = 0.2− 4 days (chopping off the initial transient and longer time points at which
the measurements are at the same level as noise). Figure 6 shows that the simple exponential decay
model fits very well the experimental data and the fitting procedure determined robust estimates for the
values of θ0 and δIT . The estimates are shown in Table 4 and across all the initial doses we find that
δIT ≈ 1.5− 1.75 day
−1 and the ratio between the initial doses are reasonably consistent with the ratios
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of I0 in θ0. Expression (4.1) suggests that the clearance of available inhibitor occurs predominantly in
tissues other than the liver, and not through binding with HPPD in the liver.
For fitting with the tyrosine data we simplified the composite solution (3.34) by removing the fast
timescale terms to a form that describes changes on an O(1) day timescale (consistent with the data),
namely
T eB = Q1 + Q2 (H(T − t)((1− e−Q3 t) + H(t−T)Q4 e−(Q3+Q5)(t−T)) , (4.2)
where
T = ln(λ) + Q6Q7 . (4.3)
Here, λ = I0/I0, where I0 and I0 are the initial available inhibitor concentrations, with the latter corre-
sponding to the blood concentration following a 1 mg/kg dose; this is the only data fitting parameter that
consists of the initial dose. The seven Qi constants are parameters to be fitted to the data and are defined
as follows in terms of the dimensional model parameters,
Q1 =
VT (δTT T1α1 (B0δH +VLk1δO)(VBα4+V 2T δTT ) + VTVLT0B0ASSδH δTT k−1α4)
VLT0B0ASSδH k−1(VBα1µ1α4 + V 2T δTT (α1 µ1 + α4 µ4)) , (4.4)
Q2 =
T1 (VBα4 + V 2T δTT )
VBT0α4 µ4
, (4.5)
Q3 = δTT , (4.6)
Q4 = ψ
[14] = VBα24µ4(VBα4+V 2T δTT )(α1µ1+α4µ4) , (4.7)
Q5 =Ω
[15]
T −δTT =
α1µ1α4
VT (α1µ1+α4µ4) , (4.8)
Q6 =
1
δIT
ln
⎛⎜⎝ I0V 2B α2µ2α3δITB0 (VBα2µ2α3+V 2T δIT (α2µ2+α3µ3))⎞⎟⎠ (4.9)
Q7 = δIT . (4.10)
The constants Q1 and Q2 are the dimensional form of T
SS
B0 (leading order pretreated blood tyrosine level)
and T [11]B0 (leading order maximum blood tyrosine level), respectively. The value t = T corresponds
to t = η12(ε)+η13(0) in the analysis, where the dose dependent term λ has been separated from the
rest of the constants in Q6. The same seven parameters were simultaneously fitted to the data for the
three doses, which are distinguished in the fitting process by setting the values of λ to be 0.5, 1 and 2 to
represent the 0.5, 1, 2 mg/kg doses, respectively. A set of fitted values are shown in Table 4(b) and Figure
7 shows that the solution curve matches reasonably well with data. As is usual when parameter fitting,
there exists numerous local minima and it was found that Q1,Q2 and Q3 were generally insensitive to
initial data, whilst there was sensitivity in the other parameters. Nevertheless, a pleasing result is that
across a broad range of initial estimates, the values for Q7 = δIT was found to be consistent with those
in Table 4(a) determined from independent data.
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(a)
dose 0.5 mg/kg 1 mg/kg 2 mg/kg
parameter units raw logged raw logged raw logged
δIT day
−1 1.56 1.50 1.72 1.74 1.50 1.74
θ0 µmole/ml 1.81 1.68 4.46 4.45 6.80 7.69
(b)
fitted parameter Q1 Q2 Q3 Q4 Q5 Q6 Q7
units µmole/ml µmole/ml day−1 none day−1 day−1 day−1
value 0.097 2.15 1.14 0.306 1.41 2.42 1.66
Table 4. Tables showing a set of estimated values from the parameter fitting procedures to data. Table (a) shows estimates of
δIT and θ0 = I0VB/µ3VT from fitting equation (4.1) to blood inhibitor concentration data between 0.2 and 4 days; all values are
robust to different initial estimates. Table (b) shows estimates of the Qis from fitting (4.2) to measured blood tyrosine data across
3 different doses; see text for discussion.
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FIG. 6. Parameter fitted solutions of blood inhibitor concentration to data for the 0.5 mg/kg (left), 1 mg/kg (middle) and 2 mg/kg
(right) cases. The fitted points are from t = 0.2 days (i.e. not accounting for the initial phase of inhibitor absorption from the
digestive tract) to t = 4 days (neglecting the outlier points that appear from t > 4 which are presumably at the noise level of the
sampling).
Contained within these Qi’s are many parameters and this analysis suggests that it is not possible
to discern all of these given the data, the best we can do is get approximate values for the relationships
indicated. The only parameters that it does help to pin down are δIT and δTT , which highlights the
important role of the tissue volume in controlling the dynamics of tyrosine and inhibitor concentrations
in the rat. A further issue highlighted by the fitting procedure is the unfortunate absence of key data
points between days 2 and 3. We observe that the model predicts that the effect of increasing the dose
is to delay the collapse of tyrosine concentration to pretreated values and more data values would help
to (1) provide more data points to establish more robust values for parameters Q4,Q5,Q6 and Q7 and
(2) verify whether or not this dose-delay relationship is true. It is worth noting from (4.3), that δIT =Q7
governs the length of the delay difference between doses.
5. Discussion
In this paper we have developed a mechanistic systems pharmacology model that covers the kinetics
and dynamics of the exposure of nitisinone in rats and its effects on tyrosine level in the liver, blood and
a generic tissue compartment. The use of asymptotic analysis has allowed us to excise the process into a
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FIG. 7. Parameter fitted solutions of blood tyrosine concentration to data for 0.5 mg/kg (left), 1 mg/kg (middle) and 2 mg/kg
(right). Each data point, indicated by the circles, is the mean of three data points, the error bars showing the minimum and
maximum data values. The solid line shows the graph of equation (4.2) using the fitted data listed in Table 4(b).
number of steps and isolate their corresponding dominant events. As a practical application, the results
of the time-scale analysis has helped us to determine which parameter combinations are identifiable from
an animal experiment that involves a single oral dose of nitisione at three doses and in which tyrosine
and inhibitor concentrations are measured only in the blood. In this scenario, we have learned that most
of the model parameters are not identifiable from these time courses. This situation could be improved if
tyrosine and inhibitor concentrations are measured in a representative tissue; however this would require
terminal animal sampling. Alternatively, parameter values may be either directly measured (in vitro or in
vivo) or predicted through the use of quantitative structure-activity relationship (QSAR) models. Finally,
we achieved a good fitting of the model to the available data at all three doses nitisinone administered,
and we were able to estimate the value of the identifiable parameter combinations for those cases.
Of particular relevance are two formulae from the asymptotic analysis:
• Formula (3.35) provides an explicit prediction of the critical concentration of the inhibitor at
which tyrosine concentration starts to build up. For a particular HPPD inhibitor, this critical con-
centration is governed by the transport and partitioning of the inhibitor across the liver/blood/tissue
phases and not by the specific values of the HPPD reaction parameters (this assumes a fast-acting
inhibitor). Since it is usually possible to predict these parameters using simple QSAR approaches,
this result is potentially very useful for finding appropriate dosing regimes.
• Formula (4.1) provides a simple description of the inhibitor decay in blood based on the partition
coefficient between blood and tissue and the inhibitor decay in tissue. It emphasises that the
critical missing measurement in many animal studies of HPPD inhibition is the decay rate of the
inhibitor in tissue.
We note that asymptotic analysis is widely applied to dynamical systems, but seems to be rarely used
for pharmacological models. This is likely due to the system sizes of these models being typically large,
making computational approaches seemingly the only option. However, though the complexity of the
analysis generally increases with system size, the underlying methodology is always the same and can,
in principle, be applied to a system of any size. The mathematics package Maple was used to under-
take some of the analysis in this paper (namely generating equations for each timescale, perform series
expansions, solving differential and algebraic equations), but the technical details of matching and es-
tablishing timescale breakdown was done by hand; as yet there does not appear to be any software that
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automates this process. The application of asymptotic analysis has its challenges, but it can provide
substantial rewards through drawing out fundamental characteristics of a model’s dynamics (hence in-
sights into the application), often in terms of relatively simple, understandable expressions that would
be difficult or impossible to obtain using other tools (e.g. in obtaining the critical concentration θ∗ in
Section 3.2). Consequently, this analytical approach should be considered part of the standard “tool kit”
used in the study of small to medium sized pharmacological models.
This model can be extended to support novel HPPD inhibitors development, either for agro-chemical
or clinical use. The model can support both single or repeat dose exposure scenarios for any HPPD
inhibitor, variable concentrations of tyrosine in blood and tissue due to different dietary patterns and
also allows for differences in TAT activation across species. Ideally, the model should rely on QSAR
predictions and/or in vitro measurements in order to minimise or eliminate animal experiments in early
research. In order to estimate the viability of this goal, we need to classify the original model parameters
into a number of groups:
• Values of the compartment volumes (VT , VB and VL) are readily available in the literature for
all three species of interest (see Brown et al. (1997)). External variable inputs like T0 (tyrosine
produced in tissue) and T1 (tyrosine introduced in the liver from the gut) are dependent on the diet.
There have been many studies in rats and humans in this area (see references below) from which to
extract appropriate estimates, although we have the added complication that T0 is tissue-specific.
Fortunately, we have direct control over another variable input, the inhibitor dose. Finally, we have
an unknown internal input which is the generation of HPPD in the liver, but we have measurements
of HPPD in the liver in both rats and mice.
• Normal tyrosine concentration measurements in the blood are available for mice, rats and humans
(Hall et al. (2001) and references below). For rats, tyrosine concentrations in the liver have also
been measured; in this species in fact, the circadian behaviour of TAT concentration has received
quite a bit of attention (Wurtman and Axelrod, 1967; Kato & Saito, 1980; Reynolds et al., 1971;
Ross et al., 1973; Cahill et al., 1981). In rats and mice, tyrosine concentration has been measured
in certain compartments like ocular fluid; in addition, TAT activity levels are also available in the
liver (Lock et al., 1996, 2000).
• Time courses in mice and rats available in the literature (Ellis et al., 1995, 1996; Lock et al.,
1996, 2000) may be enough to parametrise both the tyrosine transformation into HPPA (see also
Rosenberg & Litwack (1970)), mediated by TAT, as well as the subsequent transformation of
HPPA into homogentisic acid (mediated by homogentisic acid oxidase). Otherwise, appropriate
in vitro measurements could be made; this would be especially relevant for humans. Normal
concentrations of TAT and HPPA in the liver, tyrosine in blood and homogentisic acid, and various
phenolics in urine has been measured for rats and humans (see references above).
• For a novel inhibitor, it is possible to use QSAR models to predict transfer rates between blood and
liver and blood and tissue (parameters α2 and α3 respectively in our model), as well as partition
coefficient and plasma binding fractions. On the other hand, the binding of the inhibitor to HPPD,
can be measured in vitro to produce the appropriate values for k2 and k−2.
• As a result of the above considerations, the only parameters not available, at least theoretically,
by either QSAR modelling or in vitro measurements are the degradation constants, represented
by δ s in our model. The ones corresponding to an inhibitor (δIB , δIL , δIT ); corresponding to
blood, liver and tissue) may not play a big role for a strong binding inhibitor. The corresponding
28 of 55
ones for tyrosine (δTB , δTL , δTT ), HPPA (δP) and homogentisic acid (δR) could be computed from
the model presented in this paper, once the appropriate reaction constants (k2, k−2 and δH ) are
available. The existent of time course for concentrations of various inhibitors should provide
enough data to identify most if not all of these parameters. In fact, a predicted value for δTT (as
well as for δIT in the case of nitisinone) is already forthcoming from the computations carried out
in this paper. In any case, once these values are established, they can be used for any inhibitor of
interest without the need for re-computing them.
Consequently, it should be possible to run this model to predict tyrosine concentration in the various
compartments considered after the administration of novel HPPD inhibitors across species. Being a
mechanistic model, it does not require an array of such novel inhibitors for training purposes although
the accuracy of the model will depend on the validity of the QSAR predictors or additional in vitro and
in vivo inputs.
As well as a virtual test-bed for the development of new HPPD inhibitors, this model can be used
to illuminate the possible source of the intriguing differences in toxicity between rats and other species.
The results of the simulation seem to indicate that tyrosine measurements in the blood do not convey the
full picture; for that we need to know the concentration of tyrosine in the tissue of interest as well as in
the liver. It is possible that in rats, given the circadian nature of TAT activity, the effect of the inhibitor
is to elevate the concentration of tyrosine in the liver to the point that tyrosine is transferred in great
quantity into various tissues, causing there the observed toxicities. Perhaps, in mice and humans, HPPA
does not convert back to tyrosine but instead either accumulate harmlessly in some form in the liver or it
is simply excreted as phenolics in the urine. The model can be used to evaluate the plausibility of these
hypothesis.
The model presented in this paper looks at the effects of HPPD inhibition by nitisinone in the tyro-
sine catabolism pathway; however the model lends itself to be readily adapted to other diseases involving
this pathway. For example, alkaptonuria is a rare, painful and degenerative disease caused by a mutation
of the homogentisic acid oxidase enzyme (see Figure 1). The lack of this enzyme causes a build-up of
homogentisic acid which in turn produces the debilitating phenotype in this disease (Ferna´ndez-Can˜o´n
et al., 1996). Similar to type I tyrosinaemia, targeting HPPD with nitisinone shows some promise
(Suwannarat et al., 2005). This mathematical model could provide the basis to help predict the potential
effects of nitisinone dosing and the resultant reduction in urinary homogentisic acid over the time period
of treatment. In addition, the model can support chronic exposure scenarios and the influences of ageing
or sex differences that may introduce altered behaviour in dietary absorption of tyrosine into the liver
(input parameter T1 in the model) or in the production of the enzymes included in the model such as
HPPD (through the input parameter B0) and TAT.
Overall, the model has the scope to contribute to the reduction, replacement and refinement of animal
experimentation in research and development.
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A. Asymptotic analysis
Here we give details of the asymptotic analysis that we summarised in the Section 3. The rescalings,
equations, solutions and reasons for solution breakdown are presented for each timescale. In most cases
the matching is straightforward and details of this are generally omitted for brevity. As in Section 3,
the relevant variable rescalings for each timescale are presented first using the ↦ notation, which on
substitution into (2.8a)-(2.8j) yields the corresponding system of equations. Against formality, when
writing the timescales in the subsection headings, we treated the logarithmically large (O(ln(1/ε)))
terms the same as O(1) quantities, since they are not that large for biologically relevant values of ε;
however, in the analysis 1 ≪ ln(1/ε) is formally applied. For each timescale, a very rough indication
of the “real-world” time frame is given; these are approximations based on ε = 0.04 and t = 1≈ 16 hours
and all other parameters set to unity. Finally, it should be noted that most of the tedious algebra was
undertaken using the mathematics package Maple (version 17).
Timescale 1: t = O(ε3)
Corresponds to t = O(4)s. We introduce the scalings
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ HO,
R ↦ R, C ↦ εC, IT ↦ ε
2 IT , IB ↦
IB
ε , IL ↦ ε IL, (A.1)
and apply these to the nondimensional system (2.8) resulting in the equations
dTT
dt
= ε3 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.2a)
dTB
dt
= ε2 (α4(TT − µ4TB) + α1(TL − µ1TB)) − ε3 δTB TB, (A.2b)
dTL
dt
= ε (S1 + k1HP − k−1TL) − ε2 να1(TL − µ1TB) − ε3 δTL TL, (A.2c)
dHP
dt
= ε (k−1TL − k1HP − δHHOHP) − ε3 δPHP, (A.2d)
dHO
dt
= −ε k2HOIL + ε
3 δO (1−HO) + ε4 k−2C, (A.2e)
dR
dt
= ε (δHHOHP − δRR), (A.2f)
dC
dt
= k2HOIL − ε
3 (δC+ k−2)C, (A.2g)
dIT
dt
= α3µ3 IB − ε
3 (α3+δIT ) IT , (A.2h)
dIB
dt
= −ε2 (α2µ2+α3µ3) IB − ε3 IB + ε4α2 IL + ε5α3 IT , (A.2i)
dIL
dt
= να2µ2 IB − k2HOIL − ε
2 να2 IL + ε
3 (k−2C − δIL IL). (A.2j)
At leading order we have
TT0 = T
SS
T0 , TB0 = T
SS
B0 , TL0 = T
SS
L0 , HP0 = H
SS
P0 , (A.3)
HO0 = 1, R0 = R
SS
0 , IB0 = Θ . (A.4)
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For the remaining variables we note that d(C0+ IL0)/dt = α2µ2νΘ , and hence
IT0 = α3 µ3Θ t, IL0 =
ν α2 µ2Θ
k2
(1 − e−k2 t) , (A.5)
C0 = ν α2 µ2Θ t −
ν α2 µ2Θ
k2
(1 − e−k2 t) . (A.6)
The linear accumulation of IT0 and C0 leads to a change in balance at t = O(1/ε).
Timescale 2: t = O(ε2)
Corresponds to t = O(90)s. We rescale time such that t ↦ ε2 t and obtain the scalings
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ HO,
R ↦ R, C ↦ C, IT ↦ ε IT , IB ↦
IB
ε , IL ↦ ε IL, (A.7)
applying these to the equations (2.8) results with
dTT
dt
= ε2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.8a)
dTB
dt
= ε (α4(TT − µ4TB) + α1(TL − µ1TB)) − ε2 δTB TB, (A.8b)
dTL
dt
= S1 + k1HP − k−1TL − ε να1(TL − µ1TB) − ε2 δTL TL, (A.8c)
dHP
dt
= k−1TL − k1HP − δHHOHP − ε
2 δPHP, (A.8d)
dHO
dt
= −k2HOIL + ε
2 (δO (1−HO) + k−2C), (A.8e)
dR
dt
= δHHOHP − δRR, (A.8f)
dC
dt
= k2HOIL − ε
3 (δC+ k−2)C, (A.8g)
dIT
dt
= α3µ3 IB − ε
2 (α3+δIT ) IT , (A.8h)
dIB
dt
= −ε (α2µ2+α3µ3) IB − ε2 IB + ε3 (α2 IL + α3 IT ), (A.8i)
ε
dIL
dt
= να2µ2 IB − k2HOIL − ε
2 (να2 IL − k−2C) − ε3 δIL IL. (A.8j)
At leading order we obtain the explicit leading order solutions
TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , C0 = να2µ2Θ t, (A.9)
HO0 = 1 − να2µ2Θ t. IT0 = α3µ3Θ t, IL0 =
να2µ2Θ
k2(1 −Θνα2µ2 t) , (A.10)
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two coupled ordinary differential equations
dTL0
dt
= S1 + k1HP0 − k−1TL0 , (A.11)
dHP0
dt
= −k1HP0 + k−1TL0 − δH (1 − να2µ2Θ t) HP0 , (A.12)
and the decoupled
dR0
dt
= δH (1 − να2µ2Θ t) HP0 − δRR0. (A.13)
Here, HO0→ 0 and IL0→∞ as t→η3(ε)− <∞, where η3(0)= 1/ν α2 µ2Θ , leading to a new timescale.
Timescale 3: t = ε2η3(ε) + O(ε5/2)
Corresponds to t ≈ 90 s. Here, η3(ε) is defined such that η3(0) = 1/να2µ2Θ , and we obtain the scal-
ings: t ↦ ε2η3(ε) + ε5/2 t,
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ ε
1/2HO,
R ↦ R, C ↦ C, IT ↦ ε IT , IB ↦
IB
ε , IL ↦ ε
1/2 IL, (A.14)
and apply these to the system (2.8) resulting in
dTT
dt
= ε5/2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.15a)
dTB
dt
= ε3/2 (α4(TT − µ4TB) + α1(TL − µ1TB)) − ε5/2 δTB TB, (A.15b)
dTL
dt
= ε1/2 (S1 + k1HP − k−1TL) − ε3/2 να1(TL − µ1TB) − ε5/2 δTL TL, (A.15c)
dHP
dt
= ε1/2 (k−1TL − k1HP) − ε δHHOHP − ε5/2 δPHP, (A.15d)
dHO
dt
= −k2HOIL + ε
2 (δO + k−2C) − ε5/2 δOHO, (A.15e)
dR
dt
= −ε1/2 δRR + ε δHHOHP, (A.15f)
dC
dt
= ε1/2 k2HOIL − ε5/2 (δC+ k−2)C, (A.15g)
dIT
dt
= ε1/2α3µ3 IB − ε5/2 (α3+δIT ) IT , (A.15h)
dIB
dt
= −ε3/2 (α2µ2+α3µ3) IB − ε5/2 IB + ε3α2 IL + ε7/2α3 IT , (A.15i)
dIL
dt
= να2µ2 IB − k2HOIL− ε
3/2α2 ν IL + ε2 k−2C − ε5/2 δIL IL. (A.15j)
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All variables except HPPD, HO0 , and liver inhibitor concentration, IL0 are, at leading order, locked at
the t = η3 values on the previous timescale. namely
C0 = 1, TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , IT0 =
α3µ3
α2µ2 ν , (A.16)
TL0 = T
[2]
L0 (η3), HP0 = H[2]P0 (η3), R0 = R[2]0 (η3), (A.17)
where the superscript “[2]” represents the Timescale 2 solution.
Between the ODEs for HO0 and IL0 we deduce
IL0 = ν α2 µ2Θ t + HO0 , (A.18)
leading to a Riccati equation
dHO0
dt
= − k2HO0 (ν α2 µ2Θ t + HO0), (A.19)
which solves to give
HO0 =
√
2ν α2µ2Θ e
−k2Θ ν α2 µ2 t
2/2√
pik2 (1 + erf(√ k2Θ ν α2 µ22 t)) , (A.20)
where erf(x) = 2√pi ∫ x0 e−z2 dz; this expression for HO0 can be shown to be universally valid to leading
order for the first three timescales as ε → 0. Of particular note
HO0 ∼
√
ν α2µ2Θ e
−k2Θ ν α2 µ2 t
2/2√
2pi k2
as t →∞. (A.21)
On this timescale the HPPD concentration descends further with a balance shift when IL0HO0 = O(ε2)
and the reversible reaction between HPPD, inhibitor and complex begins to equilibrate. The balance
IL0HO0 = O(ε2) occurs when (ν α2µ2Θ)3/2√
2pik2
t e−k2Θ ν α2 µ2 t
2/2 ∼ ε2 (A.22)
which on taking logs of both sides and ordering terms for large t, we obtain
k2ν α2µ2Θ
2 t
2 − ln(t) − ln((ν α2µ2Θ)3/2√
2pik2
) = 2 ln(1/ε), (A.23)
whereupon we write t = t0+ t1+ t2+ t3+ ..., so that ti ≪ ti−1, and solve by balancing terms until we get
to a ti that effects an O(1) change; here t0 and t1 form the components of η4(ε) below and t2 balances
with the O(1) terms in (A.23).
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Timescale 4: t = ε2η3(ε) + ε5/2η4(ε) + O(ε5/2/ ln(1/ε)1/2)
Corresponds to t ≈ 120 s. Here,
η4(ε) = 2ln(1/ε)1/2√
k2να2µ2Θ
+ η41(ε) = 2ln(1/ε)1/2√
k2να2µ2Θ
+
ln(ln(1/ε))
4
√
k2να2µ2Θ ln(1/ε)1/2 , (A.24)
where η41(ε) is equal to the second term in η4. We obtain the scalings t ↦ ε2η3(ε) + ε5/2η4(ε) +
ε5/2 t/ ln(1/ε)1/2,
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦
ε5/2
ln(1/ε)1/2 HO, R ↦ R, (A.25)
C ↦ C, IT ↦ ε IT , IB ↦
IB
ε , IL ↦ ε
1/2 IL = ε1/2 (ν α2µ2Θ η4+ IL
ln(1/ε)1/2 ) ,
and apply these to the system (2.8) leads to
dTT
dt
= ε
5/2
ln(1/ε)1/2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.26a)
dTB
dt
= ε
3/2
ln(1/ε)1/2 (α4(TT − µ4TB) + α1(TL − µ1TB) − ε δTB TB) , (A.26b)
dTL
dt
= ε
1/2
ln(1/ε)1/2 (S1 + k1HP − k−1TL − ε να1(TL − µ1TB) − ε2 δTL TL) , (A.26c)
dHP
dt
= ε
1/2
ln(1/ε)1/2 (k−1TL − k1HP − ε2 δPHP − ε5/2ln(1/ε)1/2 δHHOHP) , (A.26d)
dHO
dt
=−2
√
k2να2µ2Θ HO + δO + k−2C −
k2να2µ2Θ η41
ln(1/ε)1/2 HO − k2ln(1/ε) HOIL
−
ε5/2
ln(1/ε)1/2 δOHO, (A.26e)
dR
dt
= ε
1/2
ln(1/ε)1/2 (−δRR + ε5/2ln(1/ε)1/2 δHHOHP) , (A.26f)
dC
dt
= ε
5/2
ln(1/ε)1/2 (2√k2να2µ2Θ HO − (δC+ k−2)C + k2να2µ2Θ η41ln(1/ε)1/2 HO + k2ln(1/ε) HOIL) ,
(A.26g)
dIT
dt
= ε
1/2
ln(1/ε)1/2 (α3µ3 IB − ε2 (α3+δIT ) IT ) , (A.26h)
dIB
dt
= ε
3/2
ln(1/ε)1/2 (−(α2µ2+α3µ3) IB − ε IB + ε3/2α2 IL + ε2α3 IT) , (A.26i)
dIL
dt
=να2µ2 IB − ε
3/2 ν α2 IL − ε2 (k2 ILHO − k−2C) − ε5/2 δIL IL. (A.26j)
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As with the previous timescale:
C0 = 1, TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , IT0 =
α3µ3
α2µ2 ν , (A.27)
TL0 = T
[2]
L0 (η3), HP0 = H[2]P0 (η3), R0 = R[2]0 (η3), (A.28)
and solving the ODEs for HO0 and IL0 gives
HO0 =
δO + k−2
2
√
k2να2µ2Θ
+
√
να2µ2Θ
2pik2
e−2
√
k2να2µ2Θ t , IL0 = ν α2 µ2Θ t + c1, (A.29)
where c1 is a constant of integration that requires further terms in the expansion of Timescale 3 to
determine by matching.
All variables to leading order are constant other than HO0 , which tends to a constant, and IL0 that
grows linearly. This continues until liver inhibitor concentration accumulate to IL0 = O(ln(1/ε)/ε1/2),
leading to a small balance shift in the next timescale.
Timescale 5: t = ε2η3(ε) + O(ε5/2 ln(1/ε)1/2)
Corresponds to about t =O(2−3)mins. We introduce the scalings: t ↦ ε2η3(ε)+ ε5/2 ln(1/ε)1/2 t,
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦
ε5/2
ln(1/ε)1/2 HO,
R ↦ R, C ↦ C, IT ↦ ε IT , IB ↦
IB
ε , IL ↦ ε
1/2 ln(1/ε)1/2 IL, (A.30)
and apply these to the system (2.8) gives
dTT
dt
= ε5/2 ln(1/ε)1/2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.31a)
dTB
dt
= ε3/2 ln(1/ε)1/2 (α4(TT − µ4TB) + α1(TL − µ1TB) − ε δTB TB) , (A.31b)
dTL
dt
= ε1/2 ln(1/ε)1/2 (S1 + k1HP − k−1TL − ε να1(TL − µ1TB) − ε2 δTL TL) (A.31c)
dHP
dt
= ε1/2 ln(1/ε)1/2 (k−1TL − k1HP − ε5/2
ln(1/ε)1/2 δHHOHP − ε2 δPHP) , (A.31d)
1
ln(1/ε) dHOdt = −k2HOIL + δO + k−2C − ε5/2ln(1/ε)1/2 δOHO, (A.31e)
dR
dt
= ε1/2 ln(1/ε)1/2 (−δRR + ε5/2ln(1/ε) δHHOHP) , (A.31f)
dC
dt
= ε5/2 ln(1/ε)1/2 (k2HOIL − (δC+ k−2)C) , (A.31g)
dIT
dt
= ε1/2 ln(1/ε)1/2 (α3µ3 IB − ε2 (α3+δIT ) IT ) , (A.31h)
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dIB
dt
= ε3/2 ln(1/ε)1/2 (−(α2µ2+α3µ3) IB − ε IB + ε3/2 ln(1/ε)1/2α2 IL + ε2α3 IT) ,
(A.31i)
dIL
dt
= να2µ2 IB − ε
3/2 ln(1/ε)1/2 να2 IL − ε2 (k2HOIL − k−2C) − ε5/2 ln(1/ε)1/2δIL IL.
(A.31j)
To leading order
C0 = 1, TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , IT0 =
α3µ3
α2µ2 ν , (A.32)
TL0 = T
[2]
L0 (η3), HP0 = H[2]P0 (η3), R0 = R[2]0 (η3), (A.33)
and, by matching as t → 0+,
IL0 = ν α2 µ2Θ t + 2
√
να2µ2Θ
k2
, HO0 =
δO + k−2
k2 ν α2 µ2Θ t + 2
√
k2να2µ2Θ
. (A.34)
The inhibitor continues to accumulate in the liver and HPPD continues to decline. There is a shift in
balance in the equations when t = O(ε−1/2 ln(1/ε)−1/2).
Timescale 6: t = ε2η3(ε) + O(ε2)
Corresponds to about t = O(3−5)mins. We introduce the scalings t ↦ ε2η3(ε) + ε2 t,
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ ε
3HO,
R ↦ R, C ↦ C, IT ↦ ε IT , IB ↦
IB
ε , IL ↦ IL, (A.35)
and apply to the equations (2.8) resulting in
dTT
dt
= ε2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.36a)
dTB
dt
= ε (α4(TT − µ4TB) + α1(TL − µ1TB)) − ε2 δTB TB, (A.36b)
dTL
dt
= S1 + k1HP − k−1TL − ε να1(TL − µ1TB) − ε2 δTL TL, (A.36c)
dHP
dt
= −k1HP + k−1TL − ε
2δPHP − ε
3 δHHOHP, (A.36d)
ε
dHO
dt
= −k2HOIL + δO + k−2C − ε
3 δOHO, (A.36e)
dR
dt
= −δRR + ε
3 δHHOHP, (A.36f)
dC
dt
= ε2 (k2HOIL − (δC+ k−2)C), (A.36g)
dIT
dt
= α3µ3 IB − ε
2 (α3+δIT ) IT , (A.36h)
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dIB
dt
= −ε (α2µ2+α3µ3) IB + ε2 (α2 IL − IB) + ε3α3 IT , (A.36i)
dIL
dt
= ν α2µ2 IB − ε α2 ν IL − ε
2 (k2HOIL − k−2C + δIL IL). (A.36j)
At leading order we have
C0 = 1, TT0 = T
SS
T0 , TB0 = T
SS
B0 , IB0 = Θ , (A.37)
and
IT0 =
α3µ3
α2µ2 ν + α3µ3Θ t, IL0 = να2µ2Θ t, HO0 =
δO + k−2
k2 ν α2 µ2Θ t
, R0 = R
[2]
0 (η3)e−δR t , (A.38)
HP0 = H
[2]
P0 (η3) + k−1 S1k1+ k−1 t + (1− e−(k1+k−1) t )k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) , (A.39)
TL0 = T
[2]
L0 (η3) + k1 S1k1+ k−1 t − (1− e−(k1+k−1) t )k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) . (A.40)
Here, the homogentisic acid and downstream products drop rapidly, and since in large time HOHP =
O(1), there is a shift in balance in the R equation at t = (3/δH) ln(1/ε)+O(1) when R = O(ε3).
Timescale 7: t = ε2 (η3(ε)+η7(ε)) + O(ε2)
Corresponds to about t = O(5− 8)mins. Here, η7(ε) = (3/δH) ln(1/ε) we obtain the scalings t ↦
ε2 (η3(ε)+η7(ε)) +ε2 t and
TT ↦ TT , TB ↦ TB, TL ↦ TL = η7T
C
L + TL,
HP ↦ HP = η7
k−1T
C
L
k1
+ HP, HO ↦ ε
3HO = ε
3 (HCOη7 + HOln(1/ε)2 ) , R ↦ ε3R,
C ↦ C, IT ↦ ε IT = ε (η7 ICT + IT ), IB ↦ IBε , IL ↦ IL = η7 ICL + IL, (A.41)
where TCL = k1S1/(k1 + k−1), HCO = (δO + k−2)/(k2να2µ2Θ), ICT = α3µ3Θ and ICL = να2µ2Θ .
Applying these to (2.8) we obtain
dTT
dt
= ε2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.42a)
dTB
dt
= ε (α4(TT − µ4TB) + α1(TL − µ1TB)) − ε2 δTB TB, (A.42b)
dTL
dt
= S1 + k1HP − k−1TL − ε να1(TL − µ1TB) − ε2 δTL TL, (A.42c)
dHP
dt
= −k1HP + k−1TL − ε
2δPHP − ε
3 δHHOHP, (A.42d)
ε
ln(1/ε)2 dHOdt = −k2HCO ICL + δO + k−2C − k2η7 HCO IL − k2ln(1/ε)2 HO IL − ε3 δOHO, (A.42e)
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dR
dt
= δH k−1
k1
TCL H
C
O − δRR +
δH
η7 H
C
OHP +
δH
ln(1/ε)2 HOHP, (A.42f)
dC
dt
= ε2 (k2HO IL − (δC+ k−2)C) , (A.42g)
dIT
dt
= α3µ3 IB − ε
2 (α3+δIT ) IT , (A.42h)
dIB
dt
= −ε (α2µ2+α3µ3) IB + ε2 (α2 IL − IB) + ε3α3 IT , (A.42i)
dIL
dt
= ν α2µ2 IB − ε α2 ν IL − ε
2 (k2HO IL − k−2C + δIL IL). (A.42j)
All variables except HP0 ,TL0 and R0 have the same leading order expansions as those of Timescale 6.
The exponential decay terms in HP0 and TL0 in the previous timescale have become negligible, hence,
HP0 = H
[2]
P0 (η3) + k−1 S1k1+ k−1 t + 1k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) , (A.43)
TL0 = T
[2]
L0 (η3) + k1 S1k1+ k−1 t − 1k1+ k−1 (k1T [2]L0 (η3) − k−1H[2]P0 (η3) − k−1 S1k1+ k−1 ) . (A.44)
Finally,
R0 =
S1 δH k−1 (δO+ k−2)
δR (k1+ k−1)k2 ν α2µ2Θ + R[2]0 (η3)e−δR t = R[7]min + R[2]0 (η3)e−δR t . (A.45)
On this timescale homogentisic acid reaches its minimum level, while HPPA and liver tyrosine continues
to rise. The linear growth of IT , IL,HP and TL and decay of HO0 means that a new balance in equations
will occur when t = O(ε−1/2).
Timescale 8: t = O(ε3/2)
Corresponds to about t = O(8)mins. We introduce the scalings t ↦ ε3/2 t and
TT ↦ TT , TB ↦ TB, TL ↦
TL
ε1/2 , HP ↦ HPε1/2 , HO ↦ ε7/2HO,
R ↦ ε3R, C ↦ C, IT ↦ ε
1/2 IT , IB ↦ IBε , IL ↦ ILε1/2 , (A.46)
applying them to the system (2.8) resulting in
dTT
dt
= ε3/2 (δTT (1−TT ) − α4(TT − µ4TB)) , (A.47a)
dTB
dt
= α1TL − ε
1/2 (α1µ1TB − α4(TT − µ4TB)) − ε3/2 δTB TB, (A.47b)
ε1/2 dTL
dt
= k1HP − k−1TL + ε
1/2 S1 − ε να1TL + ε3/2 ν α1µ1TB − ε2 δTL TL, (A.47c)
ε1/2 dHP
dt
= −k1HP + k−1TL − ε
2 δPHP − ε
7/2 δHHOHP, (A.47d)
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ε2
dHO
dt
= −k2HOIL + δO + k−2C − ε
7/2 δOHO, (A.47e)
ε1/2 dR
dt
= δHHOHP − δRR, (A.47f)
dC
dt
= ε3/2 (k2HOIL − (δC+ k−2)C) , (A.47g)
dIT
dt
= α3µ3 IB − ε
3/2 (α3+δIT ) IT , (A.47h)
dIB
dt
= −ε1/2 (α2µ2+α3µ3) IB + ε α2 IL − ε3/2 IB + ε2α3 IT , (A.47i)
dIL
dt
= ν α2µ2 IB − ε
1/2 ν α2 IL − ε3/2 δIL IL − ε2(k2HOIL − k−2C). (A.47j)
The following are constant to leading order
TT0 = T
SS
T0 , C0 = 1, IB = Θ , (A.48)
and the inhibitor variables decouple and solve to give
IL0 = να2µ2Θ t, IT0 = α3µ3Θ t, HO0 =
δO+ k−2
k2να2µ2Θ t
, (A.49)
Adding the 3rd and 4th ODE with ε ν× the 2nd leads to
d (HP0 +TL0)
dt
= S1, (A.50)
so HP0 + TL0 = S1 t by matching as t → 0
+. Since HP0 = k−1TL0/k1 then
TL0 =
S1 k1
k1+ k−1
t, HP0 =
S1 k−1
k1+ k−1
t, (A.51)
and hence
TB0 = T
SS
B0 +
S1 k1α1
2(k1+ k−1) t2, R0 = R[7]min. (A.52)
The inhibitor continues to increase in the liver (and tissue) and consequently HPPA increases and HPPD
continues to decrease. The increasing HPPA leads to liver tyrosine accumulating sufficiently in the liver
to affect the blood concentration. The solutions are valid until TB = O(TL) at t = O(ε−1/2).
Timescale 9: t = O(ε)
Corresponds to about t = O(40− 60)mins. On this timescale we rescale time such that t ↦ ε t and
introduce the scalings
TT ↦ TT , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
4HO,
R ↦ ε3R, C ↦ C, IT ↦ IT , IB ↦
IB
ε , IL ↦
IL
ε , (A.53)
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which are applied to the equations (2.8) leads to
dTT
dt
= α4µ4TB + ε (δTT (1−TT ) − α4TT ) , (A.54a)
dTB
dt
= α1TL − (α1µ1 + α4µ4)TB + ε (α4TT − δTB TB), (A.54b)
ε
dTL
dt
= k1HP − k−1TL + ε (S1 − να1TL + ν α1µ1TB) − ε2 δTL TL, (A.54c)
ε
dHP
dt
= −k1HP + k−1TL − ε
2 δPHP − ε
4 δHHOHP, (A.54d)
ε3
dHO
dt
= −k2HOIL + δO + k−2C − ε
4 δOHO, (A.54e)
ε
dR
dt
= δHHOHP − δRR, (A.54f)
dC
dt
= ε (k2HOIL − (δC+ k−2)C) , (A.54g)
dIT
dt
= α3µ3 IB − ε (α3+δIT ) IT , (A.54h)
dIB
dt
= −(α2µ2+α3µ3) IB + α2 IL + ε (α3 IT − IB), (A.54i)
dIL
dt
= ν α2(µ2 IB − IL) − ε δIL IL − ε2 (k2HOIL − k−2C). (A.54j)
We have the quasi-steady solutions
C0 = 1, HP0 =
k−1
k1
TL0 , HO0 =
δO + k−2
k2 IL0
, (A.55)
where TL0 and IL0 are derived below. At leading order HP0 = k−1TL0/k1. Adding the equations for TL
and HP leads to the system
dTT0
dt
= α4µ4TB0 ,
dTB0
dt
= α1TL0 − (α1µ1 + α4µ4)TB0 , (A.56)(1+ k−1
k1
) dTL0
dt
= S1 − α1 (TL0 − µ1TB0), (A.57)
the latter two ODEs reduce to
d2TB0
dt2
+ ( k1να1
k1+ k−1
+ α1µ1+α4µ4) dTB0dt + k1να1α4µ4k1+ k−1 TB0 = S1k1α1k1+ k−1 , (A.58)
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subject to, by matching, TB0 = dTB0/dt = 0 at t = 0. This solves to give
TB0 =
S1
να4µ4
⎛⎜⎝1 + ω− eω
+t
ω+−ω−
−
ω+ eω
−t
ω+−ω−
⎞⎟⎠ , (A.59)
TT0 =T
SS
T0 +
S1
ν
⎛⎜⎜⎜⎝ t − ω
− (1− eω+t)
ω+(ω+−ω−) + ω+ (1− eω
−t)
ω−(ω+−ω−)⎞⎟⎟⎟⎠ , (A.60)
TL0 =
S1 (α1µ1+α4µ4)
να1α4µ4 +
S1
να1α4µ4 (ω+−ω−) (A.61)(ω−(α1µ1+α4µ4+ω+)eω+t + ω+(α1µ1+α4µ4+ω−)eω−t) , (A.62)
where
ω± = −12 ( k1να1k1+ k−1 + α1µ1+α4µ4) ± 12 (( k1να1k1+ k−1 + α1µ1−α4µ4)2 + 4α1µ1α4µ4)1/2 , (A.63)
and it can be shown that ω− < ω+ < 0.
The equations for the inhibitor are decoupled and combine to give
d2IB0
dt2
+ (α3µ3 + α2(µ2+ν)) dIB0dt + να2α3µ3 IB0 = 0, (A.64)
which solves to
IL0 =
Θ ν α2 µ2
ρ+−ρ−
(eρ+t − eρ−t) , (A.65)
IB0 =
Θ
ρ+−ρ−
((ρ++ α2µ2 + α3µ3)eρ−t − (ρ−+ α2µ2 + α3µ3)eρ+t) , (A.66)
IT0 =Θ (1 + (ρ−+α2µ2+α3µ3)(ρ++α2(µ2+ν)+α3µ3)α2 ν (ρ+−ρ−) eρ+t (A.67)
−
(ρ++α2µ2+α3µ3)(ρ−+α2(µ2+ν)+α3µ3)
α2 ν (ρ+−ρ−) eρ−t) (A.68)
where
ρ ± = − (α3 µ3 + α2 (µ2+ν))2 ± 12 (α3µ3 + α2 (µ2+ν))2 − 4ν α2α3 µ3)1/2 ,
and that ρ− < ρ+ < 0. The remaining variable is
R0 =
δHHOHP
δR
= δH k1 (δO + k−2)
δR k2
TL0
IL0
.
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Of particular note is behaviour as t →∞ namely,
TB0 ∼
S1
να4µ4 = T
[9]
B∞ , TT0 ∼
S1
ν t, TL0 ∼
S1 (α1µ1+α4µ4)
να1α4µ4 = T
[9]
L∞ ,
IL0 ∼
Θ ν α2 µ2
ρ+−ρ−
eρ
+t
, IB0 ∼
Θ
ρ+−ρ−
(−(ρ−+ α2µ2 + α3µ3)) eρ+t , IT0 ∼ Θ ,
HP0 ∼
S1 k1(α1µ1+α4µ4)
k−1να1α4µ4
= H[9]P∞ , HO0 ∼ (δO + k−2)(ρ+−ρ−)k2 ν α2 µ2Θ e−ρ+t ,
R0 ∼
S1 δH k1(α1µ1+α4µ4)(δO + k−2)(ρ+−ρ−)
δR k−1k2ν2α1α4µ4α2µ2Θ
e−ρ
+t
.
Blood tyrosine has reached a (temporary) maximum and tissue concentrations are rising. Inhibitor
concentration in the blood and eventually in the liver declines as it infiltrates into tissue acting as an
inhibitor sink. As the liver inhibitor concentration declines, HPPD and homogentisic acid starts to rise.
There is a shift in balance when IB0 = O(ε) and IL0 = O(ε), i.e. t = ln(1/ε)/(−ρ+)+O(1).
Timescale 10: t = ε η10(ε) + O(ε)
Corresponds to about t = O(5) hours. Here, η10(ε) = ln(1/ε)/(−ρ+) we scale time such that t ↦
ε η10(ε) + ε t and introduce
TT ↦ TT = η10
S1
ν +TT , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
3HO,
R ↦ ε2R, C ↦ C, IT ↦ IT , IB ↦ IB, IL ↦ IL. (A.70)
Applying these to the equations of the previous timescale we obtain
dTT
dt
= α4µ4TB + ε (δTT (1−TT ) − α4TT ) , (A.71a)
dTB
dt
= α1TL − (α1µ1 + α4µ4)TB + ε (α4TT − δTB TB), (A.71b)
ε
dTL
dt
= k1HP − k−1TL + ε (S1 − να1TL + ν α1µ1TB) − ε2 δTL TL, (A.71c)
ε
dHP
dt
= −k1HP + k−1TL − ε
2 δPHP − ε
3 δHHOHP, (A.71d)
ε2
dHO
dt
= −k2HOIL + δO + k−2C − ε
3 δOHO, (A.71e)
ε
dR
dt
= δHHOHP − δRR, (A.71f)
dC
dt
= ε (k2HOIL − (δC+ k−2)C) , (A.71g)
dIT
dt
= ε (α3 (IT − µ3 IB) − δIT IT ), (A.71h)
dIB
dt
= α2 (IL − µ2 IB) + α3 (IT − µ3 IB) − ε IB, (A.71i)
dIL
dt
= −ν α2 (IL − µ2 IB) − ε (k2HOIL − k−2C + δIL IL). (A.71j)
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Through matching as t → −∞ we obtain
C0 = 1, TB0 = T
[9]
B∞ , TL0 = T
[9]
L∞ , HP0 = H
[9]
P∞ , IT0 = Θ , (A.72)
and we can deduce
TT0 =
S1
ν t. (A.73)
Constant IT0 leads to
d2IB0
dt2
+ (α3µ3 + α2(µ2+ν)) dIB0dt + να2α3µ3 IB0 = να2α3Θ , (A.74)
which on solution and matching yields
IB0 =
Θ
µ3 −Θ
(ρ−+ α2µ2 + α3µ3)
ρ+−ρ−
eρ
+t
, (A.75)
IL0 =
µ2Θ
µ3 +
Θνα2µ2
ρ+−ρ−
eρ
+t
, (A.76)
and δO + k−2C0 − k2HO0 IL0 = 0 gives
HO0 =
µ3 (ρ+−ρ−)(δO + k−2)
Θ k2 µ2 (ρ+−ρ− + να2µ3 eρ+t) , (A.77)
and
R0 =
δH
δR
H[9]P∞ HO0 . (A.78)
The inhibitor concentration is equilibrating throughout as with all variables, except tissue tyrosine which
is increasing. The HPPD concentration is still very low as is homogentisic acid. The continued increase
of TT0 leads to a balance shift when TT0 = O(1/ε), i.e. t = O(1/ε).
Timescale 11: t = O(1)
Corresponds to about t =O(16−24) hours. On this timescale time is O(1) and we introduce the scalings
TT ↦
TT
ε , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
3HO,
R ↦ ε2R, C ↦ C, IT ↦ IT , IB ↦ IB, IL ↦ IL. (A.79)
which are applied to the equations for the previous timescale
dTT
dt
= −δTT TT − α4 (TT −µ4TB) + ε δTT , (A.80a)
ε
dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTB TB, (A.80b)
46 of 55 REFERENCES
ε2
dTL
dt
= k1HP − k−1TL + ε (S1 − α1 ν (TL−µ1TB)) − ε2 δTLTL, (A.80c)
ε2
dHP
dt
= −k1HP + k−1TL − ε
2 δPHP − ε
3 δHHOHP, (A.80d)
ε3
dHO
dt
= δO + k−2C − k2HOIL − ε
3 δOHO, (A.80e)
ε2
dR
dt
= δHHOHP − δRR, (A.80f)
dC
dt
= k2HOIL − (k−2+δC)C, (A.80g)
dIT
dt
= −α3 (IT −µ3 IB) − δIT IT , (A.80h)
ε
dIB
dt
= α2 (IL−µ2 IB) + α3 (IT −µ2 IB) − ε IB, (A.80i)
ε
dIL
dt
= −α2 ν (IL−µ2 IB) − ε (k2HOIL − k−2C + δIL IL) . (A.80j)
At leading order the equations representing the inhibitor solve to give
IT0 = Θ e
−δIt t , IB0 =
Θ
µ3 e
−δIt t , IL0 =
Θ µ2
µ3 e
−δIt t . (A.81)
Adding the leading order equations for C and HO leads to
dC0
dt
= δO − δCC0 ⇒ C0 =
δO
δC
+ (1− δO
δC
) e−δC t . (A.82)
where matching implies C0(0) = 1, which gives
HO0 =
µ3
k2µ2Θ
(δO (1+ k−2δC )+(1− δOδC ) e−δC t) eδIT t . (A.83)
Adding εν× the TT and TB equations with those of TL and HP leads to, at leading order,
dTT0
dt
= S1ν − δTT TT0 , (A.84)
hence
TT0 =
S1
ν δTT
(1 − e−δTT t) , TB0 = S1ν α4 µ4 + S1ν δTT µ4 (1 − e−δTT t) , (A.85)
TL0 =
S1 (α1µ1+α4µ4)
να1α4µ4 +
S1 µ1
νδTT µ4
(1 − e−δTT t) , (A.86)
HP0 =
S1 k−1 (α1µ1+α4µ4)
k1να1α4µ4
+
S1 k−1µ1
k1νδTT µ4
(1 − e−δTT t) . (A.87)
Finally, at leading order, R0 = δHHOHP/δR.
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As stated in the main text, the maximum value for TB in the numerical solution is rather poorly
predicted by the leading order approximation of the maximum corresponding to TB0 as t →∞, namely
TB0 ∼
S1
ν µ4 ( 1α4 + 1δTT ) = T [11]B∞ , (A.88)
where for ε ≈ 0.04 the error is about 40-50%. This cannot be explained from the leading order expan-
sion, and examination of the correction terms is needed to see why such an error can arise. Continuing
on to the first correction term for TB, we find that,
dTB1
dt
= −δTT TB1 − δTT T
[11]
B1∞ + A
[11]
0 e
−δTT t , (A.89)
where
T [11]B1∞ =− S1(α4+δTT )((δTLk1+δPk−1)(α1µ1α4+δTT (α1µ1+α4µ4))+ k1δTBνα1(α4+δTT ))k1ν2δ 2TTα1α24µ24 + 1µ4 ,
(A.90)
A[11]0 =S1 (νk1(δTB −δTT )+µ1(k1(δTL −δTT )+ k−1(δP−δTT )))k1ν2δTT µ24 , (A.91)
for which we obtain the solution
TB1 = T
[11]
B1∞
+ (A[11]0 t + A[11]1 ) e−δTT t , (A.92)
where A[11]1 is a constant of integration that could be determined by matching with the correction terms
of the previous timescale (not undertaken). Here, TB1 → T
[11]
B1∞
as t →∞, which turns out to make up a
large part of the error in the prediction of the maximum of TB.
The other variables tends to the following at leading order,
TT0 ∼
S1
ν δTT
= T [11]T∞ , TL0 ∼ S1νµ4 ( µ1δTT + µ1α4 + µ4α1 ) = T [11]L∞ , (A.93)
HP0 ∼
S1 k−1
k1νµ4
( µ1
δTT
+
µ1
α4 +
µ4
α1 ) = H[11]P∞ , C0 ∼ δOδC . (A.94)
as t →∞. The blood tyrosine solution will be part of that used to fit with data. The decay rate of
inhibitor will also be matched with data.
The inhibitor, HPPD and homogentisic acid either decays or grows exponentially and there is shift
in balance when t = ln(1/ε)/δIT +O(1).
Timescale 12: t = η12(ε) + O(1)
Corresponds to about t =O(2) days. Here, η12(ε)= (1/δIT ) ln(1/ε) we rescale time such that t ↦ η12(ε)+
t and introduce
TT ↦
TT
ε , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
2HO,
R ↦ ε R, C ↦ C, IT ↦ ε IT , IB ↦ ε IB, IL ↦ ε IL, (A.95a)
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which when applied to system (2.8) result in the following
dTT
dt
= −δTT TT − α4 (TT −µ4TB) + ε δTT , (A.95b)
ε
dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTB TB, (A.95c)
ε2
dTL
dt
= k1HP − k−1TL + ε (S1 − α1 ν (TL−µ1TB)) − ε2 δTLTL, (A.95d)
ε2
dHP
dt
= −k1HP + k−1TL − ε
2 (δPHP − δHHOHP) , (A.95e)
ε2
dHO
dt
= δO + k−2C − k2HOIL − ε
2 δOHO, (A.95f)
ε2
dR
dt
= δHHOHP − δRR, (A.95g)
dC
dt
= k2HOIL − (k−2+δC)C, (A.95h)
dIT
dt
= −α3 (IT −µ3 IB) − δIT IT , (A.95i)
ε
dIB
dt
= α2 (IL−µ2 IB) + α3 (IT −µ2 IB) − ε IB, (A.95j)
ε
dIL
dt
= −α2 ν (IL−µ2 IB) − k2HOIL + k−2C − ε δIL IL. (A.95k)
By matching, at leading order the following are constant
TT0 = T
[11]
T∞ , TB0 = T
[11]
B∞ , TL0 = T
[11]
L∞ , HP0 = H
[11]
P∞ , C0 =
δO
δC
. (A.96)
Adding the ODEs for IT , IB, IL/ν and C/ν leads to
dIT0
dt
= δOν − δIT IT0 , (A.97)
which provides on solution
IL0 =
Θ µ2
µ3 e
−δIT t −
δO
νµ3 ( µ2δIT + µ2α3 + µ3α2 ) , (A.98)
IB0 =
Θ
µ3 e
−δIT t −
δO
νµ3 ( 1δTT + 1α3 ) = IL0µ2 + δOν α2 µ2 = IL0µ2 + I[12]Bc , (A.99)
IT0 =Θ e
−δIT t −
δO
ν δIT
= µ3µ2 IL0 +
δO (α2µ2+α3µ3)
ν α2 µ2α3 =
µ3
µ2 IL0 + I
[12]
Tc , (A.100)
HO0 =
δO(δC + k−2)
k2 δC (Θ µ2µ3 e−δIT t − δOνµ3 ( µ2δIT + µ2α3 + µ3α2 )) , (A.101)
R0 =
S1 k−1 δH δO (δC + k−2)
δRδC k1 ν µ4 k2 (Θ µ2µ3 e−δIT t − δOνµ3 ( µ2δIT + µ2α3 + µ3α2 )) (
µ1
δTT
+
µ1
α4 +
µ4
α1 ) . (A.102)
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The inhibitor is continuing to drop and HPPD levels are rising, but still low so that tyrosine levels
remains at their peak. Breakdown of the current balance occurs when, as it turns out,
Θ µ2
µ3 e
−δIT t −
δO
νµ3 ( µ2δIT + µ2α3 + µ3α2 ) = O(ε2/3), (A.103)
i.e.
t = 1
δIT
ln( Θ ν α2 µ2α3 δIT
δO (α2α3 + δIT (α2µ2+α3µ3))) + O(ε2/3). (A.104)
Timescale 13: t = η12(ε) + η13(ε) + O(ε2/3)
Corresponds to about t ≈ 3 days. Here, η13(ε) is such that
η13(0) = (1/δIT ) ln[Θ ν α2 µ2α3 δIT /δO (α2 µ2α3 + δIT (α2µ2+α3µ3))] .
We rescale time such that t ↦ η12(ε) + η13(ε) + ε2/3 t, and obtain the scalings
TT ↦
TT
ε , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ ε
4/3HO, R ↦ ε1/3R,
C ↦ C, IT ↦ ε IT = ε I
[12]
Tc + ε
5/3IT , IB ↦ ε IB = ε I[12]Bc + ε5/3IB, IL ↦ ε5/3 IL. (A.105)
applying these to equations (2.8) to get
dTT
dt
= −ε2/3 (δTT TT + α4 (TT −µ4TB)) + ε5/3 δTT , (A.106a)
ε1/3 dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTB TB, (A.106b)
ε4/3 dTL
dt
= k1HP − k−1TL + ε (S1 − α1 ν (TL−µ1TB)) − ε2 δTLTL, (A.106c)
ε4/3 dHP
dt
= −k1HP + k−1TL − ε
2 (δPHP − δHHOHP) , (A.106d)
ε2/3 dHO
dt
= δO + k−2C − k2HOIL − ε
2 δOHO, (A.106e)
ε4/3 dR
dt
= δHHOHP − δRR, (A.106f)
dC
dt
= ε2/3 (k2HOIL − (k−2+δC)C), (A.106g)
dIT
dt
= −α3 (I[12]Tc −µ3 I[12]Bc ) − δIT I[12]Tc − ε2/3 (α3 (IT −µ3 IB) + δIT IT ), (A.106h)
ε
dIB
dt
= α3 ( I[12]Tc −µ3 I[12]Bc ) − α2 µ2 I[12]Bc + ε2/3 (α3 (IT −µ3 IB) + α2 (IL−µ2 IB)) − ε IB,
(A.106i)
ε
dIL
dt
= να2µ2 I
[12]
Bc − k2HOIL + k−2C − ε
2/3 να2 (IL−µ2 IB) − ε5/3 δIL IL. (A.106j)
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To leading order, the following are constant,
TT0 = T
[11]
T∞ , TB0 = T
[11]
B∞ , TL0 = T
[11]
L∞ , HP0 = H
[11]
P∞ , C0 =
δO
δC
. (A.107)
Integrating the tissue inhibitor equation gives, on matching,
IT0 = −
δO
ν α2 µ2α3 ϒ
[13]
I t, (A.108)
where ϒ [13]I = α2µ2α3 + δIT (α2 µ2 + α3 µ3). Once again the liver inhibitor and HPPD are in quasi-
steady state so that
IL0 =
δO + k−2 δO/δC
k2HO0
, IB0 =
α3 IT0 + α2 IL0
α2 µ2 + α3 µ3 . (A.109)
Adding the ODEs for HO and −IL leads to, at O(ε4/3),
dHO0
dt
= −ν α2 (µ2 IB0 − IL0), (A.110)
which eventually yields
dHO0
dt
=
δOϒ
[13]
I
α2µ2 + α3µ3 t +
ν α2α3 µ3(δO+ k−2δO/δC)
k2 (α2µ2+α3µ3) 1HO0 . (A.111)
This has solutions in terms of Airy functions and matching with Timescale 12 solutions means that
HO0 ∼ (−t)−1να2α3µ3(1+ k−2/δC)/k2ϒ [13]I as t → −∞. Given the solution HO, then
IL0 =
δO + k−2 δO/δC
k2HO0
, IB0 =
α2(δO + k−2 δO/δC)
k2 (α2µ2+α3µ3)HO0 − δOϒ
[13]
I
ν α2µ2(α2µ2+α3µ3) t, (A.112)
and R0 = δHHO0H
[11]
P0 /δR.
In large time we have
HO0 ∼
δOϒ
[13]
I
2(α2µ2 + α3µ3) t 2, IL0 ∼ 2α2 (α2µ2 + α3µ3)(δO+ k−2δO/δC)k2 δOϒ [13]I 1t 2 . (A.113)
and IT0 = O(1/t) and IB0 = O(1/t).
Inhibitor concentrations fall rapidly in the liver as HPPD recovers over this fast timescale. Tyrosine
and HPPA concentrations are static and homogenistic acid increases to near pretreated state. It turns out
there is a shift in balance when t = O(ε−1/6) when HO0 = O(ε−1/3) and IL0 = O(ε−1/3).
Timescale 14: t = η12(ε) + η13(ε) + O(ε1/2)
Corresponds to about t ≈ 3 days. We introduce the scalings: t ↦ η12(ε) + η13(ε) + ε1/2 t,
TT ↦
TT
ε , TB ↦
TB
ε , TL ↦
TL
ε , HP ↦
HP
ε , HO ↦ εHO, R ↦ R,
C ↦ C, IT ↦ ε IT = ε I
[12]
Tc + ε
3/2IT , IB ↦ ε IB = ε I[12]Bc + ε3/2IB, IL ↦ ε2 IL, (A.114)
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and apply them to equations (2.8) resulting in the system
dTT
dt
= −ε1/2 (δTT TT + α4 (TT −µ4TB)) + ε3/2 δTT , (A.115a)
ε1/2 dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTB TB, (A.115b)
ε3/2 dTL
dt
= k1HP − k−1TL + ε (S1 − α1 ν (TL−µ1TB)) − ε2 δTLTL, (A.115c)
ε3/2 dHP
dt
= −k1HP + k−1TL + ε δHHOHP − ε
2 δPHP, (A.115d)
ε1/2 dHO
dt
= δO + k−2C − k2HOIL − ε δOHO, (A.115e)
ε3/2 dR
dt
= δHHOHP − δRR, (A.115f)
dC
dt
= ε1/2 (k2HOIL − (δC+ k−2)C), (A.115g)
dIT
dt
= −α3 (I[12]Tc −µ3 I[12]Bc ) − δIT I[12]Tc − ε1/2 (α3 (IT −µ3 IB) + δIT IT ), (A.115h)
ε
dIB
dt
= α3 (I[12]Tc −µ3 I[12]Bc ) − α2 µ2 I[12]Bc + ε1/2 (α3 (IT −µ3 IB) + α2 (IL−µ2 IB)) − ε IB,
(A.115i)
ε3/2 dIL
dt
= να2µ2 I
[12]
Bc − k2HOIL + k−2C + ε
1/2 ν α2 µ2 IB − ε ν α2 IL − ε2 δIL IL. (A.115j)
To leading order, the following are constant
TT0 = T
[11]
T∞ , C0 =
δO
δC
. (A.116)
By matching
IT0 = −
δOϒ
[13]
I
ν α2 µ2α3 t, IB0 = −
δOϒ
[13]
I
ν α2 µ2 (α2µ2+α3µ3) t, (A.117)
and, in particular,
HO0 =
δOϒ
[13]
I
2(α2µ2 + α3µ3) t 2, IL0 = 2(α2µ2 + α3µ3)k−2k2 δCϒ [13]I 1t 2 , (A.118)
i.e. the large time solutions of the previous timescale continue on. With tissue tyrosine being constant,
the blood/liver tyrosine and HPPA satisfy the simultaneous equation
(α1µ1+α4µ4)TB0 − α1TL0 = S1α4ν δTT , k1HP0 − k−1TL0 = 0, (A.119)
να1µ1TB0 − να1TL0 − δHHO0 HP0 = −S1, (A.120)
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where HO0 is given above, which, expressing the solutions in terms of the matched initial conditions,
solves to give
TB0 =
1 + ψΨ [14]0 t2
1 +Ψ [14]0 , t2 T
[11]
B∞ , TL0 =
1
1 +Ψ [14]0 t2 T
[11]
L∞ , HP0 =
1
1 +Ψ [14]0 t2 H
[11]
P∞ , (A.121)
where
ψ [14] = α24 µ4(α4+δTT )(α1 µ1+α4 µ4) , Ψ [14]0 = δO δH k−1ϒ
[13]
I (α1 µ1+α4 µ4)
2k1 ν α1α4 µ4 (α2 µ2+α3 µ3) , (A.122)
noting that ψ [14] < 1. Finally for homogentisic acid
R0 =
δO δHϒ
[13]
I H
[11]
P∞
2δR (α2µ2 + α3µ3) t 2(1 +Ψ0 t2 ) . (A.123)
In large time we have
TB0 ∼ ψ
[14]T [11]B∞ = T [14]B∞ , TL0 ∼ T
[11]
L∞
Ψ [14]0
1
t2
, HP0 ∼
H[11]P∞
Ψ [14]0
1
t2
, (A.124)
R0 ∼
δO δHϒ
[13]
I H
[11]
P∞
2δRΨ0 (α2µ2 + α3µ3) = R[14]∞ . (A.125)
As HPPD is increasing the liver tyrosine and HPPA start to decline. The approximations breakdown in
this timescale at t = O(ε−1/2), when TL and HP are reduced by O(ε) and HO increase by O(1/ε).
Timescale 15: t = η12(ε) + η13(ε) + O(1)
Corresponds to about t ≈ 3−4 days. We rescale time such that t ↦ η12(ε) + η13(ε) + t and introduce
the scalings
TT ↦
TT
ε , TB ↦
TB
ε , TL ↦ TL, HP ↦ HP, HO ↦ HO,
R ↦ R, C ↦ C, IT ↦ ε IT , IB ↦ ε IB, IL ↦ ε
3 IL. (A.126)
Applying these to the equations (2.8) we obtain
dTT
dt
= −δTT TT − α4 (TT −µ4TB) + ε δTT , (A.127a)
ε
dTB
dt
= −α1 µ1TB + α4 (TT −µ4TB) + ε (α1TL − δTB TB), (A.127b)
ε2
dTL
dt
= S1 + k1HP − k−1TL − α1 ν (TL−µ1TB) − ε2 δTLTL, (A.127c)
ε2
dHP
dt
= −k1HP + k−1TL + δHHOHP − ε
2 δPHP, (A.127d)
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dHO
dt
= δO + k−2C − k2HOIL − δOHO, (A.127e)
ε2
dR
dt
= δHHOHP − δRR, (A.127f)
dC
dt
= k2HOIL − (k−2+δC)C, (A.127g)
dIT
dt
= −α3 (IT −µ3 IB) − δIT IT , (A.127h)
ε
dIB
dt
= α3 (IT −µ3 IB) − µ2 IB − ε IB + ε2α2 IL, (A.127i)
ε3
dIL
dt
= ν α2 µ2 IB − k2HOIL + k−2C − ε
2 ν α2 IL − ε
3 δIL IL. (A.127j)
Combining the first two equations leads to
TT0 = T
[11]
T∞ e
−Ω [15]T t , TB0 = T [14]B∞ e−Ω [15]T t , (A.128)
where Ω [15]T = (α1µ1α4+δTT (α1µ1+α4µ4))/(α1µ1+α4µ4) and recalling that T [11]T∞ = S1/ν δTT and
T [14]B∞ = ψ [14] S1 (α4+δTT )δTT ν α4 µ4 = S1α4δTT ν (α1 µ1+α4 µ4) . (A.129)
Combining equations for IT and IB gives
IT0 = I
[12]
Tc e
−Ω [15]I t , IB0 = I[12]Bc e−Ω [15]I t , (A.130)
where Ω [15]I = (α2µ2α3+δIT (α2µ2+α3µ3))/(α2µ2+α3µ3), I[12]Bc = δO/να2µ2 and I[12]Tc = δO(α2µ2+
α3µ3)/να2µ2α3. Adding the ODEs for HO and −IL yields
dHO0
dt
= δO(1−HO0) + να2µ2 IB0 ⇒ HO0 = 1 − φ(t)φ(0) , (A.131)
using I[12]Bc = δO/να2µ2 and where
φ(t) =Ω [15]I e−δOt −δOe−Ω [15]I t , (A.132)
noting that φ(t)→ 0 as t →∞. Likewise adding C and IL gives
dC0
dt
= ν α2 µ2 IB0 − δCC0 ⇒ C0 =
δO
δC
φc(t)
φc(0) , (A.133)
using the matching condition C0(0) = δO/δC and where φc(t) = Ω [15]I e−δC t − δC e−Ω [15]I t , noting that
φc(t)→ 0 as t →∞. Between the equations for HP and TL we have
HP0 = H
SS
P0 +
S1 φ(t) + ν α1 µ1 φ(0)T [14]B0 e−Ω [15]T t
δH (φ(0)−φ(t)) , (A.134)
TL0 = T
SS
L0 +
S1 k1 φ(t) + ν α1 µ1T [14]B0 e−Ω [15]T t (φ(0)(δH + k1)−δH φ(t))
δH k−1 (φ(0) − φ(t)) . (A.135)
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For homogentisic acid,
R0 = R
SS
0 −
δH
δR
⎛⎜⎜⎜⎝ φ(t)φ(0)HSSP0 + (1− φ(t)φ(0))
⎛⎜⎜⎜⎝S1 φ(t) + ν α1 µ1 φ(0)T
[14]
B0 e
−Ω [15]T t
δH (φ(0)−φ(t)) ⎞⎟⎟⎟⎠
⎞⎟⎟⎟⎠ . (A.136)
To leading order IL satisfies
IL0 =
ν α2 µ2 I
[12]
Bc e
−Ω [15]I t + k−2 δO φc(t)/δC φc(0)
k2 (1−φ(t)/φ(0)) (A.137)
In large time we have
TL0 ∼ T
SS
L0 , HP0 ∼ H
SS
P0 , HO0 ∼ 1, R0 ∼ R
SS
0 , (A.138)
i.e. at their pretreated concentrations. Inhibitor and complex concentrations are such that they have
negligible effects at leading order. Blood and tissue tyrosine concentrations are in decline, but still high.
The blood and tissue tyrosine decay exponentially and eventually reaches the order of magnitude of the
pretreated state in t = ln(1/ε)/Ω [15]T +O(1).
Timescale 16: t = η12(ε) + η13(ε) + η16(ε) + O(1)
Corresponds to about t =O(4) days. Here, η16(ε)= ln(1/ε)/Ω [15]T = (α1µ1+α4µ4) ln(1/ε)/(α1µ1α4+
δTT (α1µ1+α4µ4)), we rescale time such that t ↦ η12(ε) + η13(ε) + η16(ε) + t and introduce the
scalings
TT ↦ TT , TB ↦ TB, TL ↦ TL, HP ↦ HP, HO ↦ HO, R ↦ R, C ↦ ε
min{Ω [15]I ,δC}/Ω [15]T C,
IT ↦ ε
1+Ω [15]I /Ω [15]T IT , IB ↦ ε1+Ω [15]I /Ω [15]T IB, IL ↦ ε3+min{Ω [15]I ,δC}/Ω [15]T IL; (A.139)
the scalings on the complex and inhibitor variables mean they make negligible contribution at leading
order.
The following are at their pretreated concentrations
TL0 = T
SS
L0 , HP0 = H
SS
P0 , HO0 = 1, R0 = R
SS
0 , (A.140)
and the equations for the leading order blood and tissue tyrosine are
dTT
dt
= δTT (1−TT ) − α4 (TT −µ4TB) , (A.141a)
ε
dTB
dt
= α1 (TL−µ1TB) + α4 (TT −µ4TB) − ε δTBTB, (A.141b)
whereby solving and matching gives
TT0 = T
SS
T0 +
S1
ν δTT
e−Ω
[15]
T t , (A.142)
TB0 = T
SS
B0 +
S1α4
δTT ν (α1 µ1+α4 µ4) e−Ω [15]T t , (A.143)
recalling that Ω [15]T = (α1µ1α4+ δTT (α1µ1+α4µ4))/(α1µ1+α4µ4) and hence TT0 → T SST0 and TB0 →
T SSB0 as t →∞.
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B. Animal Experimentation
Male Han Wistar Crl:WI rats (Charles River UK Ltd., Kent) were acclimatised for a period of 7 days
prior to dosing and the non-GLP experimental design was based on OECD guidelines No. 417 for
Toxicokinetics. Throughout the studies, the rats had access to domestic water and diet —PMI Nutrition
International Certified Rodent Diet No. 5CR4 (14% protein)— ad libitum. Husbandry practices and
environmental enrichment were as Test Facility SOPs (Charles River UK Ltd., Edinburgh). All animals
were checked each day for viability, received detailed clinical examination prior to dosing and were
monitored for reaction to treatment.
Three rats, approximately 9 to 10 weeks old and weighing between 297 and 337 g, were dosed with
either vehicle only or 0.5 mg/kg, 1 mg/kg or 2 mg/kg nitisinone (S02F832242K Syngenta Ltd., Switzer-
land). The vehicle consisted of 0.5% concentration (w/v) carboxymethylcellulose (CMC), medium
viscosity (Sigma, UK) with 0.5% (v/v) Tween 80 (Sigma, Switzerland) in water, and the nitisinone
(S02F832242K, Syngenta Ltd., Switzerland) formulations were prepared from a stock solution at 0.2
mg/mL, both prepared on the day of administration. Each dosing formulation was administered to the
rats by a single oral gavage dose using a graduated syringe with a plastic cannula attached in a volume
of 10 mL/kg.
Blood samples (approximately 100 µL) were collected from the lateral tail vein from each rat using
a hypodermic needle into dry-coated potassium-EDTA vessels at the following time points after dosing:
0, 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 144 and 168 h. Immediately following collection, 50 µL
of whole blood from each sample, was accurately measured into a plain plastic tube holding 50 µL of
Milli Q water. Tubes were placed on a roller mixer for approximately 1 minute and then frozen on dry
ice pending storage at -80 degrees Celsius.
Samples were analysed under the test conditions set out by the laboratory (Bioanalytical Laboratory
at Charles River, Edinburgh) for concentration of nitisinone and tyrosine after protein precipitation in
either acetonitrile or acetone, respectively. Samples were analysed on a API4000, AB Sciex mass spec-
trometer with a micro HPLC pump and vacuum degasser (Series 200, Perkin Elmer), an autosampler
(HTS Pal, CTC Analytics) and Analyst Version 1.4.2, AB Sciex data handling system. The samples
were separated on a Kinetex PFP, 50 x 2.1 mm, 2.6 µm Phenomenex column with a Prefit 0.5 µm
Anachan guard column using the following mobile phases: for nitisinone mobile phase A- acetonitrile
/ formic acid (100/0.1, v/v) and mobile phase B- 10 mM ammonium acetate / formic acid (100/0.1,
v/v), and for tyrosine mobile phase A- acetonitrile and mobile phase B- 10 mM ammonium acetate
/ formic acid (100/0.1, v/v). Nifedipine was used as the internal standard for the nitisinone samples,
whilst the tyrosine measurements were conducted in the absence of an internal standard. Sample con-
centrations of nitisinone and tyrosine were calculated from respective calibration curves in accordance
to the acceptance criteria outline by the Bioanalytical Laboratory.
